Document:

SUBSCRIPTION AGREEMENT

 

Cell Source, Ltd.

65 Yigal Alon Street, 23rd Floor

Tel Aviv 67433, Israel

 

Ladies and Gentlemen:

 

1.          Subscription.
The undersigned (the “Purchaser”), intending to be legally bound, hereby irrevocably agrees to purchase from Cell
Source, Ltd. (the “Company” or “Cell Source”) the number of units (the “Units”) set forth on
the signature page hereof at a purchase price of $0.75 per Unit. Each Unit consists of (i) one share of the Company’s Ordinary
Shares, each of nominal value of NIS 0.01 (the “Ordinary Shares”) and (ii) a 5 year warrant (each, a “Warrant”
and collectively, the “Warrants”) to purchase one share of Ordinary Shares at an exercise price of $0.75 per share.

 

2.          This
subscription is submitted to you in accordance with and subject to the terms and conditions described in this Subscription Agreement
and the Confidential Private Placement Memorandum of Cell Source dated November 13, 2013, as amended or supplemented from time
to time, including all attachments, schedules and exhibits thereto (the “Memorandum”), relating to the offering (the
“Offering”) by the Company of a minimum of 666,667 Units ($500,000) (“Minimum Offering Amount”), and up
to a maximum of 2,666,667 Units ($2,000,000) (“Maximum Offering Amount”). The terms of the Offering are more completely
described in the Memorandum and such terms are incorporated herein in their entirety.

 

3.          Effect
of the Sale of Maximum Offering Amount. In the event of a closing pursuant to which the aggregate Units sold in the Offering
is equal to or greater than the Maximum Offering Amount (“Maximum Offering Closing”), within 120 days of the Maximum
Offering Closing, Cell Source shall consummate a transaction (the “Acquisition”) in which Cell Source and all of Cell
Source’s shareholder, including all the Purchasers in this Offering, would enter into a share exchange with a public company
(“Pubco”). If the Acquisition is consummated, Cell Source will become a wholly-owned subsidiary of Pubco. Accordingly,
Pubco, through its subsidiary Cell Source and with the proceeds of this Offering, would continue the existing business operations
of Cell Source as a publicly-traded company. Since the closings of this Offering will occur prior to the Acquisition, the Purchaser
will not know the identity of Pubco prior to the Maximum Offering Closing. However, the Purchaser hereby absolutely and irrevocably
agrees, acknowledges, covenants and represents that the Purchaser consents to the Acquisition and the Purchaser shall enter into
any agreements required to consummate the Acquisition, the effects of which were described in the Memorandum to the satisfaction
of the Purchaser and are incorporated herein in their entirety. If the Acquisition has not been completed within 120 days of the
Maximum Offering Closing, then for each 30 day period that the Acquisition has not closed, the purchase price for the Units will
be reduced by $0.10 and Cell Source shall immediately issue to each Investor such number of Ordinary Shares that would result in
the effective purchase price of the Units purchased by such Investor to be equal to the reduced price of the Unit, provided that
the effective price shall not be lower than $.25 per Unit.

 

    	A-1

    	 

    

 

4.          Payment.
The Purchaser encloses herewith a check payable to, or will immediately make a wire transfer payment to, “Signature Bank,
Escrow Agent for Cell Source, Ltd.” in the full amount of the purchase price of the Units being subscribed for. Wire transfer
instructions are set forth on page 14 hereof under the heading “To subscribe for Units in the private offering of Cell Source,
Ltd.” Such funds will be held for the Purchaser's benefit, and will be returned promptly, without interest or offset if this
Subscription Agreement is not accepted by the Company, the Offering is terminated pursuant to its terms by the Company prior to
the First Closing (as hereinafter defined), or the Minimum Offering Amount is not sold. Together with a check for, or wire transfer
of, the full purchase price, the Purchaser is delivering a completed and executed Omnibus Signature Page to this Subscription Agreement
and the Registration Rights Agreement, in the form of Exhibit C to the Memorandum (the “Registration Rights Agreement”).

 

5.          Deposit
of Funds. All payments made as provided in Section 4 hereof shall be deposited with Signature Bank (the “Escrow Agent”),
in a non-interest-bearing escrow account (the “Escrow Account”) until the earliest to occur of (a) the closing of the
sale of the Minimum Offering Amount (the “First Closing”), (b) the rejection of such subscription, and (c) the termination
of the Offering by the Cell Source. Cell Source may continue to offer and sell the Units and conduct additional closings for the
sale of additional Units after the First Closing and until the termination of the Offering.

 

6.          Acceptance
of Subscription. The Purchaser understands and agrees that the Company, in its sole discretion, reserves the right to accept
or reject this or any other subscription for Units, in whole or in part, notwithstanding prior receipt by the Purchaser of notice
of acceptance of this subscription. The Company shall have no obligation hereunder until the Company shall execute and deliver
to the Purchaser an executed copy of this Subscription Agreement. If this subscription is rejected in whole, the Offering of Units
is terminated or the Minimum Offering Amount is not raised, all funds received from the Purchaser will be returned without interest
or offset, and this Subscription Agreement shall thereafter be of no further force or effect. If this subscription is rejected
in part, the funds for the rejected portion of this subscription will be returned without interest or offset, and this Subscription
Agreement will continue in full force and effect to the extent this subscription was accepted.

 

7.           Representations
and Warranties

 

The Purchaser hereby acknowledges, represents, warrants, and
agrees as follows:

 

a)            None of the
shares of Ordinary Shares or the shares of Ordinary Shares issuable upon exercise of the Warrants (the “Warrant Shares”)
offered pursuant to the Memorandum are registered under the Securities Act of 1933, as amended (the “Securities Act”),
or any state securities laws. The Purchaser understands that the offering and sale of the Units is intended to be exempt from registration
under the Securities Act, by virtue of Section 4(2) thereof and the provisions of Regulation D (“Regulation D”) as
promulgated by the United States Securities and Exchange Commission (the “SEC”) thereunder, based, in part, upon the
representations, warranties and agreements of the Purchaser contained in this Subscription Agreement;

 

b)            Prior to the
execution of this Subscription Agreement, the Purchaser and the Purchaser's attorney, accountant, purchaser representative and/or
tax adviser, if any (collectively, the “Advisers”), have received the Memorandum and all other documents requested
by the Purchaser, have carefully reviewed them and understand the information contained therein;

 

    	A-2

    	 

    

 

c)            Neither the
Securities and Exchange Commission nor any state securities commission or other regulatory authority has approved the Units, the
Ordinary Shares, the Warrants or the Warrant Shares, or passed upon or endorsed the merits of the offering of Units or confirmed
the accuracy or determined the adequacy of the Memorandum. The Memorandum has not been reviewed by any federal, state or other
regulatory authority;

 

d)            All documents,
records, and books pertaining to the investment in the Units (including, without limitation, the Memorandum) have been made available
for inspection by such Purchaser and its Advisers, if any;

 

e)            The Purchaser
and its Advisers, if any, have had a reasonable opportunity to ask questions of and receive answers from a person or persons acting
on behalf of the Company concerning the offering of the Units and the business, financial condition and results of operations of
Cell Source, and all such questions have been answered to the full satisfaction of the Purchaser and its Advisers, if any;

 

f)             In
evaluating the suitability of an investment in the Company, the Purchaser has not relied upon any representation or information
(oral or written) other than as stated in the Memorandum;

 

g)           The Purchaser
is unaware of, is in no way relying on, and did not become aware of the Offering of the Units through or as a result of, any form
of general solicitation or general advertising including, without limitation, any article, notice, advertisement or other communication
published in any newspaper, magazine or similar media or broadcast over television, radio or the Internet (including, without limitation,
internet “blogs,” bulletin boards, discussion groups and social networking sites) in connection with the Offering and
sale of the Units and is not subscribing for the Units and did not become aware of the Offering of the Units through or as a result
of any seminar or meeting to which the Purchaser was invited by, or any solicitation of a subscription by, a person not previously
known to the Purchaser in connection with investments in securities generally;

 

h)            The Purchaser
has taken no action that would give rise to any claim by any person for brokerage commissions, finders' fees or the like relating
to this Subscription Agreement or the transactions contemplated hereby (other than as described in the Memorandum);

 

i)            
The Purchaser, together with its Advisers, if any, has such knowledge and experience in financial, tax, and business matters,
and, in particular, investments in securities, so as to enable it to utilize the information made available to it in
connection with the Offering to evaluate the merits and risks of an investment in the Units and the Company and to make an
informed investment decision with respect thereto;

 

j)            The
Purchaser is not relying on the Company or any of its employees or agents with respect to the legal, tax, economic and related
considerations of an investment in the Units, and the Purchaser has relied on the advice of, or has consulted with, only its own
Advisers;

 

    	A-3

    	 

    

 

k)            The Purchaser
is acquiring the Units solely for such Purchaser's own account for investment purposes only and not with a view to or intent of
resale or distribution thereof, in whole or in part. The Purchaser has no agreement or arrangement, formal or informal, with any
person to sell or transfer all or any part of the Units, the shares of Ordinary Shares, the Warrants or the Warrant Shares, and
the Purchaser has no plans to enter into any such agreement or arrangement;

 

l)            The
Purchaser must bear the substantial economic risks of the investment in the Units indefinitely because none of the securities included
in the Units may be sold, hypothecated or otherwise disposed of unless subsequently registered under the Securities Act and applicable
state securities laws or an exemption from such registration is available. Legends shall be placed on the securities included in
the Units to the effect that they have not been registered under the Securities Act or applicable state securities laws and appropriate
notations thereof will be made in the Company's stock books. Appropriate notations will be made in the Company's stock books to
the effect that the securities included in the Units have not been registered under the Securities Act or applicable state securities
laws. Stop transfer instructions will be placed with the transfer agent of the Units. The Company has agreed that purchasers of
the Units will have, with respect to the shares of Ordinary Shares and the Warrant Shares, the registration rights described in
the Registration Rights Agreement. Notwithstanding such registration rights, there can be no assurance that there will be any market
for resale of the Units, the Ordinary Shares, the Warrants or the Warrant Shares, nor can there be any assurance that such securities
will be freely transferable at any time in the foreseeable future;

 

m)            The Purchaser
has adequate means of providing for such Purchaser's current financial needs and foreseeable contingencies and has no need for
liquidity of its investment in the Units for an indefinite period of time;

 

n)            The Purchaser
is aware that an investment in the Units is high risk, involving a number of very significant risks and has carefully read and
considered the matters set forth under the caption “Risk Factors” in the Memorandum, and, in particular, acknowledges
that Cell Source has a limited operating history, significant operating losses since inception, no revenues to date, limited assets
and is engaged in a highly competitive business;

 

o)            The Purchaser
meets the requirements of at least one of the suitability standards for an “accredited investor” as that term is defined
in Regulation D and as set forth on the Accredited Investor Certification contained herein;

 

    	A-4

    	 

    

 

p)            The Purchaser
(i) if a natural person, represents that the Purchaser has reached the age of 21 and has full power and authority to execute and
deliver this Subscription Agreement and all other related agreements or certificates and to carry out the provisions hereof and
thereof; (ii) if a corporation, partnership, or limited liability company or partnership, or association, joint stock company,
trust, unincorporated organization or other entity, represents that such entity was not formed for the specific purpose of acquiring
the Units, such entity is duly organized, validly existing and in good standing under the laws of the state of its organization,
the consummation of the transactions contemplated hereby is authorized by, and will not result in a violation of state law or its
charter or other organizational documents, such entity has full power and authority to execute and deliver this Subscription Agreement
and all other related agreements or certificates and to carry out the provisions hereof and thereof and to purchase and hold the
securities constituting the Units, the execution and delivery of this Subscription Agreement has been duly authorized by all necessary
action, this Subscription Agreement has been duly executed an delivered on behalf of such entity and is a legal, valid and binding
obligation of such entity; or (iii) if executing this Subscription Agreement in a representative or fiduciary capacity, represents
that it has full power and authority to execute and deliver this Subscription Agreement in such capacity and on behalf of the subscribing
individual, ward, partnership, trust, estate, corporation, or limited liability company or partnership, or other entity for whom
the Purchaser is executing this Subscription Agreement, and such individual, partnership, ward, trust, estate, corporation, or
limited liability company or partnership, or other entity has full right and power to perform pursuant to this Subscription Agreement
and make an investment in the Company, and represents that this Subscription Agreement constitutes a legal, valid and binding obligation
of such entity. The execution and delivery of this Subscription Agreement will not violate or be in conflict with any order, judgment,
injunction, agreement or controlling document to which the Purchaser is a party or by which it is bound;

 

q)            The Purchaser
and the Advisers, if any, have had the opportunity to obtain any additional information, to the extent Cell Source have such information
in its possession or could acquire it without unreasonable effort or expense, necessary to verify the accuracy of the information
contained in the Memorandum and all documents received or reviewed in connection with the purchase of the Units and have had the
opportunity to have representatives of Cell Source provide them with such additional information regarding the terms and conditions
of this particular investment and the financial condition, results of operations, business of Cell Source deemed relevant by the
Purchaser or the Advisers, if any, and all such requested information, to the extent Cell Source had such information in its possession
or could acquire it without unreasonable effort or expense, has been provided to the full satisfaction of the Purchaser and the
Advisers, if any;

 

r)            Any
information which the Purchaser has heretofore furnished or is furnishing herewith to Cell Source is complete and accurate and
may be relied upon by Cell Source and gent in determining the availability of an exemption from registration under federal and
state securities laws in connection with the offering of securities as described in the Memorandum. The Purchaser further represents
and warrants that it will notify and supply corrective information to Cell Source immediately upon the occurrence of any change
therein occurring prior to Cell Source’s issuance of the securities contained in the Units;

 

s)            The Purchaser
has significant prior investment experience, including investment in non-listed and non-registered securities. The Purchaser is
knowledgeable about investment considerations in companies with limited operating histories. The Purchaser has a sufficient net
worth to sustain a loss of its entire investment in the Company in the event such a loss should occur. The Purchaser's overall
commitment to investments which are not readily marketable is not excessive in view of the Purchaser’s net worth and financial
circumstances and the purchase of the Units will not cause such commitment to become excessive. The investment is a suitable one
for the Purchaser;

 

t)            The
Purchaser is satisfied that the Purchaser has received adequate information with respect to all matters which it or the Advisers,
if any, consider material to its decision to make this investment;

 

u)            The Purchaser
acknowledges that any estimates or forward-looking statements or projections included in the Memorandum were prepared by Cell Source
in good faith but that the attainment of any such projections, estimates or forward-looking statements cannot be guaranteed by
Cell Source and should not be relied upon;

 

    	A-5

    	 

    

 

v)            No oral or written
representations have been made, or oral or written information furnished, to the Purchaser or the Advisers, if any, in connection
with the Offering which are in any way inconsistent with the information contained in the Memorandum;

 

w)           Within five
(5) days after receipt of a request from the Cell Source, the Purchaser will provide such information and deliver such documents
as may reasonably be necessary to comply with any and all laws and ordinances to which Cell Source is subject;

 

x)            THE SECURITIES
OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND ARE BEING
OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SAID ACT AND SUCH LAWS. THE SECURITIES ARE SUBJECT
TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER SAID ACT AND SUCH
LAWS PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. THE SECURITIES HAVE NOT BEEN RECOMMENDED, APPROVED OR DISAPPROVED BY THE
SECURITIES AND EXCHANGE COMMISSION, ANY STATE SECURITIES COMMISSION OR ANY OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING
AUTHORITIES PASSED UPON OR ENDORSED THE MERITS OF THIS OFFERING OR THE ACCURACY OR ADEQUACY OF THE MEMORANDUM OR THIS SUBSCRIPTION
AGREEMENT. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL;

 

y)            In making an
investment decision investors must rely on their own examination of the Company, Cell Source and the terms of the Offering, including
the merits and risks involved. The Purchaser should be aware that it will be required to bear the financial risks of this investment
for an indefinite period of time;

 

z)            (For ERISA
plans only) The fiduciary of the ERISA plan (the “Plan”) represents that such fiduciary has been informed of and
understands the Company’s investment objectives, policies and strategies, and that the decision to invest “plan assets”
(as such term is defined in ERISA) in the Company is consistent with the provisions of ERISA that require diversification of plan
assets and impose other fiduciary responsibilities. The Purchaser fiduciary or Plan (a) is responsible for the decision to invest
in the Company; (b) is independent of the Company or any of its affiliates; (c) is qualified to make such investment decision;
and (d) in making such decision, the Purchaser fiduciary or Plan has not relied primarily on any advice or recommendation of the
Company or any of its affiliates;

 

aa)          The
Purchaser should check the Office of Foreign Assets Control (“OFAC”) website at <http://www.treas.gov/ofac> before
making the following representations. The Purchaser represents that the amounts invested by it in the Company in the Offering
were not and are not directly or indirectly derived from activities that contravene federal, state or international laws and regulations,
including anti-money laundering laws and regulations. Federal regulations and Executive Orders administered by OFAC prohibit, among
other things, the engagement in transactions with, and the provision of services to, certain foreign countries, territories, entities
and individuals. The lists of OFAC prohibited countries, territories, persons and entities can be found on the OFAC website at
<http://www.treas.gov/ofac>. In addition, the programs administered by OFAC (the “OFAC Programs”) prohibit dealing
with individuals1 or entities in certain countries regardless of whether such individuals or entities appear on the
OFAC lists;

 

 

1 These individuals include specially designated
nationals, specially designated narcotics traffickers and other parties subject to OFAC sanctions and embargo programs

 

    	A-6

    	 

    

 

bb)         To
the best of the Purchaser’s knowledge, none of: (1) the Purchaser; (2) any person controlling or controlled by the Purchaser;
(3) if the Purchaser is a privately-held entity, any person having a beneficial interest in the Purchaser; or (4) any person for
whom the Purchaser is acting as agent or nominee in connection with this investment is a country, territory, individual or entity
named on an OFAC list, or a person or entity prohibited under the OFAC Programs. The Purchaser acknowledges that the Company may
not accept any amounts from a prospective investor if such prospective investor cannot make the representation set forth in the
preceding paragraph. The Purchaser agrees to promptly notify the Company should the Purchaser become aware of any change in the
information set forth in these representations. The Purchaser understands and acknowledges that, by law, the Company may be obligated
to “freeze the account” of the Purchaser, either by prohibiting additional subscriptions from the Purchaser, declining
any redemption requests and/or segregating the assets in the account in compliance with governmental regulations, and a placement
agent, if any, may also be required to report such action and to disclose the Purchaser’s identity to OFAC. The Purchaser
further acknowledges that the Company may, by written notice to the Purchaser, suspend the redemption rights, if any, of the Purchaser
if the Company reasonably deems it necessary to do so to comply with anti-money laundering regulations applicable to the Company
or any of the Company’s other service providers. These individuals include specially designated nationals, specially designated
narcotics traffickers and other parties subject to OFAC sanctions and embargo programs;

 

cc) 
       To the best of the Purchaser’s knowledge, none of: (1) the Purchaser; (2) any
person controlling or controlled by the Purchaser; (3) if the Purchaser is a privately-held entity, any person having a
beneficial interest in the Purchaser; or (4) any person for whom the Purchaser is acting as agent or nominee in connection
with this investment is a senior foreign political figure,2 or any immediate family3 member or close
associate4 of a senior foreign political figure, as such terms are defined in the footnotes below; and

 

dd) 
       If the Purchaser is affiliated with a non-U.S. banking institution (a
“Foreign Bank”), or if the Purchaser receives deposits from, makes payments on behalf of, or handles other
financial transactions related to a Foreign Bank, the Purchaser represents and warrants to the Company that: (1) the Foreign
Bank has a fixed address, other than solely an electronic address, in a country in which the Foreign Bank is authorized to
conduct banking activities; (2) the Foreign Bank maintains operating records related to its banking activities; (3) the
Foreign Bank is subject to inspection by the banking authority that licensed the Foreign Bank to conduct banking activities;
and (4) the Foreign Bank does not provide banking services to any other Foreign Bank that does not have a physical presence
in any country and that is not a regulated affiliate.

 

 

2 A “senior foreign political
figure” is defined as a senior official in the executive, legislative, administrative, military or judicial branches of
a foreign government (whether elected or not), a senior official of a major foreign political party, or a senior executive of
a foreign government- owned corporation. In addition, a “senior foreign political figure” includes any
corporation, business or other entity that has been formed by, or for the benefit of, a senior foreign political figure.

 

3
“Immediate family” of a senior foreign political figure typically includes the figure’s parents, siblings,
spouse, children and in-laws.

 

4 A “close
associate” of a senior foreign political figure is a person who is widely and publicly known to maintain an unusually close
relationship with the senior foreign political figure, and includes a person who is in a position to conduct substantial domestic
and international financial transactions on behalf of the senior foreign political figure.

 

    	A-7

    	 

    

  

8.             Indemnification.
The Purchaser agrees to indemnify and hold harmless the Company, and its respective officers, directors, employees, agents,
control persons and affiliates, from and against all losses, liabilities, claims, damages, costs, fees and expenses whatsoever
(including, but not limited to, any and all expenses incurred in investigating, preparing or defending against any litigation commenced
or threatened) based upon or arising out of any actual or alleged false acknowledgment, representation or warranty, or misrepresentation
or omission to state a material fact, or breach by the Purchaser of any covenant or agreement made by the Purchaser herein or in
any other document delivered in connection with this Subscription Agreement.

 

9.             Binding
Effect. The Purchaser hereby acknowledges and agrees that the subscription hereunder is irrevocable by the Purchaser, except
as required by applicable law, and that this Subscription Agreement shall survive the death or disability of the Purchaser and
shall be binding upon and inure to the benefit of the parties and their heirs, executors, administrators, successors, legal representatives,
and permitted assigns. If the Purchaser is more than one person, the obligations of the Purchaser hereunder shall be joint and
several and the agreements, representations, warranties, and acknowledgments herein shall be deemed to be made by and be binding
upon each such person and such person's heirs, executors, administrators, successors, legal representatives, and permitted assigns.

 

10.           Modification.
This Subscription Agreement shall not be modified or waived except by an instrument in writing signed by the party against
whom any such modification or waiver is sought.

 

11.         
Immaterial Modifications to the Registration Rights Agreement. The Company may, at any time prior to the Acquisition, modify
the Registration Rights Agreement if necessary to clarify any provision therein, without first providing notice or obtaining prior
consent of the Purchaser, if, and only if, such modification is not material in any respect.

 

12.         
Notices. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be
mailed by certified mail, return receipt requested, or delivered against receipt to the party to whom it is to be given (a) if
to Cell Source, at the address set forth above, or (b) if to the Purchaser, at the address set forth on the signature page hereof
(or, in either case, to such other address as the party shall have furnished in writing in accordance with the provisions of this
Section 12). Any notice or other communication given by certified mail shall be deemed given at the time of certification thereof,
except for a notice changing a party's address which shall be deemed given at the time of receipt thereof.

 

    	A-8

    	 

    

 

13.          Assignability.
This Subscription Agreement and the rights, interests and obligations hereunder are not transferable or assignable by the Purchaser
and the transfer or assignment of the shares of Ordinary Shares or the Warrants shall be made only in accordance with all applicable
laws.

 

14.         
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the United States of America
and the State of New York, both substantive and remedial, without regard to New York conflicts of law principles. Any judicial
proceeding brought against either of the parties to this Agreement or any dispute arising out of this Agreement or any matter related
hereto shall be brought in the courts of the State of New York, New York County, or in the United States District Court for the
Southern District of New York and, by its execution and delivery of this Agreement, each party to this Agreement accepts the jurisdiction
of such courts. The foregoing consent to jurisdiction shall not be deemed to confer rights on any person other than the parties
to this Agreement.

 

15.           Blue
Sky Qualification. The purchase of Units under this Subscription Agreement is expressly conditioned upon the exemption from
qualification of the offer and sale of the Units from applicable federal and state securities laws. The Company shall not be required
to qualify this transaction under the securities laws of any jurisdiction and, should qualification be necessary, the Company shall
be released from any and all obligations to maintain its offer, and may rescind any sale contracted, in the jurisdiction.

 

16.           Use
of Pronouns. All pronouns and any variations thereof used herein shall be deemed to refer to the masculine, feminine, neuter,
singular or plural as the identity of the person or persons referred to may require.

 

17.           Confidentiality.
The Purchaser acknowledges and agrees that any information or data the Purchaser has acquired from or about Cell Source, not
otherwise properly in the public domain, was received in confidence. The Purchaser agrees not to divulge, communicate or disclose,
except as may be required by law or for the performance of this Agreement, or use to the detriment of Cell Source or for the benefit
of any other person or persons, or misuse in any way, any confidential information of Cell Source, including any scientific, technical,
trade or business secrets of Cell Source and any scientific, technical, trade or business materials that are treated by Cell Source
as confidential or proprietary, including, but not limited to, ideas, discoveries, inventions, developments and improvements belonging
to Cell Source and confidential information obtained by or given to Cell Source about or belonging to third parties.

 

18.           Miscellaneous.

 

(a)         This Subscription
Agreement, together with the Registration Rights Agreement, constitute the entire agreement between the Purchaser and the Company
with respect to the subject matter hereof and supersede all prior oral or written agreements and understandings, if any, relating
to the subject matter hereof. The terms and provisions of this Subscription Agreement may be waived, or consent for the departure
therefrom granted, only by a written document executed by the party entitled to the benefits of such terms or provisions.

 

    	A-9

    	 

    

 

(b)          The
representations and warranties of the Company and the Purchaser made in this Subscription Agreement shall survive the execution
and delivery hereof and delivery of the shares of Ordinary Shares and Warrants contained in the Units.

 

(c)           Each
of the parties hereto shall pay its own fees and expenses (including the fees of any attorneys, accountants, appraisers or others
engaged by such party) in connection with this Subscription Agreement and the transactions contemplated hereby whether or not the
transactions contemplated hereby are consummated.

 

(d)          This
Subscription Agreement may be executed in one or more counterparts each of which shall be deemed an original, but all of which
shall together constitute one and the same instrument.

 

(e)           Each
provision of this Subscription Agreement shall be considered separable and, if for any reason any provision or provisions hereof
are determined to be invalid or contrary to applicable law, such invalidity or illegality shall not impair the operation of or
affect the remaining portions of this Subscription Agreement.

 

(f)           Paragraph
titles are for descriptive purposes only and shall not control or alter the meaning of this Subscription Agreement as set forth
in the text.

 

(g)          The
Purchaser understands and acknowledges that there may be multiple closings for this Offering.

 

(h)          Provided
that the First Closing has occurred with respect to the sale of the Units pursuant to this Subscription Agreement, the Company
agrees that:

 

(i)         For
a period commencing on the closing of the Offering and terminating five years from the closing of the Offering, in the event the
Company (or Pubco) issues or grants any shares of Ordinary Shares or securities convertible, exchangeable or exercisable for Ordinary
Shares pursuant to which Ordinary Shares may be acquired at a price less than $0.75 per share (“Adjustment Event”),
subject to proportionate adjustments from time to time upon the occurrence of a subdivision, combination, dividend, split, reclassification
or reorganization of the Company or the Ordinary Shares, then the Company shall promptly issue additional Ordinary Shares to the
Investors under this Offering in an amount sufficient that the subscription price paid hereunder, when divided by the total number
of shares issued, will result in an actual price paid by such Investor per share of Ordinary Shares is equal to such lower price,
except this right shall not apply to any issuances or grants related to securities convertible, exchangeable or exercisable
for Ordinary Shares outstanding or anti-dilution rights existing at the time of this Agreement, this right shall not apply to any
Investor who, at the time of the Adjustment Event, holds less than 50% of such Investor’s original holdings in the Company
and this right shall not apply to options issued to employees and service providers as part of an employee stock option plan (ESOP).

 

    	A-10

    	 

    

 

(ii)        For
a period commencing on the closing of the Offering and terminating five years from the closing of the Offering,
upon any financing by the Company of Ordinary Shares or securities convertible into Ordinary Shares (a "Subsequent
Financing"), Investors under this offering shall have the right to participate in any Subsequent Financing (subject to customary
exemptions).

 

(i)          Provided
that the Maximum Offering Amount is sold, the Investors may elect up to two (2) independent board members to serve on the Company’s
Board of Directors or, if after the Acquisition, the Board of Directors of Pubco;

 

(j)          At
the closing of the Acquisition, the note of the Company in the principal amount of $510,000 shall be cancelled and exchanged for
a total of 18% of the currently outstanding Ordinary Shares.

 

(k)         Immediately
prior to the First Closing, the Company shall have up to 15,000,000 Ordinary Shares issued and outstanding and no debt.

 

(l)          Immediately
prior to the closing of the Acquisition, the Company shall have entered into lockup agreements with (i) certain affiliate shareholders
of Pubco that shall expire one year from the date the Acquisition is consummated and (ii) with all current shareholders of the
Company that shall expire two years from the date the Acquisition is consummated.

 

(m)        Provided
that the Acquisition is consummated and the Registration Statement (as defined by the Registration Rights Agreement) is declared
effective, certain founders of the Company, Isaac Braun, Saar Dickman, Itamar Shimrat and Yoram Drucker, shall be issued warrants
to purchase an aggregate of 3,000,000 Ordinary Shares at an exercise price of $0.75 per share, subject to the same adjustments
and terms as the Warrants sold in this Offering.

 

19.          Omnibus
Signature Page. This Subscription Agreement is intended to be read and construed in conjunction with the Registration Rights
Agreement pertaining to the issuance by the Company of the shares of Ordinary Shares and Warrants to subscribers pursuant to the
Memorandum. Accordingly, pursuant to the terms and conditions of this Subscription Agreement and such related agreements it is
hereby agreed that the execution by the Purchaser of this Subscription Agreement, in the place set forth herein, shall constitute
agreement to be bound by the terms and conditions hereof and the terms and conditions of the Registration Rights Agreement, with
the same effect as if each of such separate but related agreement were separately signed.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

    	A-11

    	 

    

 

Instructions

 

To subscribe for Units in the private offering of Cell Source,
Ltd.:

 

1.           Date
and Fill in the number of Units being purchased and Complete and Sign the attached Omnibus Signature Page to the
Subscription Agreement and Registration Agreement.

 

2.           Initial
the Accredited Investor Certification (United States Resident or Canadian Resident, as applicable) page attached hereto.

 

3.           Complete
and Sign the Investor Profile and, if applicable, Wire Transfer Authorization attached to this letter.

 

4.           Complete
and Sign the Selling Stockholder Questionnaire.

 

5.           Delivery
Instructions of the Omnibus Signature Page, Accredited Investor Certification page, Investor Profile and, if applicable, Wire
Transfer Authorization, shall be obtained by contacting Itamar Shimrat, Chief Executive Officer of Cell Source, who may be reached
at 011 972 52 444-9977 or ishimrat@cell-source.com.

 

6.           Please
make your subscription payment payable to the order of “Signature Bank, Escrow Agent for Cell Source,
Ltd”

 

For wiring funds directly to the escrow account, see
the following instructions:

 

	 	Bank:	Signature Bank
	 	Acct. Name:	Signature Bank as Escrow Agent for
	 	 	Cell Source, Ltd
	 	 	950 Third Avenue, 9th Floor
	 	 	New York, NY 10022
	 	ABA Number:	026013576
	 	A/C Number:	1501957360
	 	FBO:	Investor Name
	 	 	Social Security Number
	 	 	Address

 

    	A-12

    	 

    

 

All funds tendered by Investors will be
held in a non-interest bearing escrow account in the Company’s name at Signature Bank, 950 Third Avenue, 9th Floor,
New York, NY 10022. It is contemplated that the funds will be released from escrow at such time (or promptly thereafter) as all
conditions to closing as set forth in the Subscription Agreement have been satisfied (or otherwise waived) and a closing is consummated.
It is contemplated that in the event that the Company does not provide written instructions to Signature Bank with respect to the
disbursement of funds on or before December 5, 2013 (subject to an extension until no later than January 4, 2013) the Company will
refund all subscription funds, without interest accrued thereon or deduction therefrom, and will return the documents previously
delivered to each subscriber, and such documents will be terminated and of no force or effect.

 

Questions regarding completion of the
attached Transaction Documents should be directed to Itamar Shimrat, Chief Executive Officer of Cell Source, who may be reached
at 011 972 52 444-9977 or ishimrat@cell-source.com.

 

Thank you for your interest,

 

Cell Source, Ltd.

 

    	A-13

    	 

    

 

ANTI MONEY LAUNDERING REQUIREMENTS 

 

	The USA PATRIOT Act	 	What is money 

laundering?	 	How big is the problem 

and why is it important?
	
         

        The USA PATRIOT Act is designed to detect, deter, and punish
        terrorists in the United States and abroad. The Act imposes new anti- money laundering requirements on brokerage firms and financial

        institutions. Since April 24,

        2002 all brokerage firms have been required to have new, comprehensive
        anti- money laundering programs.

         

        To help you understand these efforts, we want to provide you
        with some information about money laundering and, if applicable, a placement agent’s efforts to implement the USA PATRIOT
        Act.
	 	
         

        Money laundering is the process of disguising illegally obtained
        money so that the funds appear to come from legitimate sources or activities.

        Money laundering occurs in connection with a wide variety of
        crimes, including illegal arms sales, drug trafficking, robbery, fraud, racketeering, and terrorism.
	 	
         

        The use of the U.S. financial system by criminals to facilitate
        terrorism or other crimes could well taint our financial markets. According to the U.S. State Department, one recent estimate puts
        the amount of worldwide money laundering activity at $1 trillion a year.

 

	What the Placement Agent is required to do to help eliminate money laundering?
	 	 	 
	Under new rules required by the USA PATRIOT Act, if there is a placement agent, its anti-money laundering program must designate a special compliance officer, set up employee training, conduct independent audits, and establish policies and procedures to detect and report suspicious transaction and ensure compliance with the new laws.	 	If applicable, as part of the required program, it may ask you to provide various identification documents or other information and until you provide the information or documents that it needs, it may not be able to effect any transactions for you.

 

    	A-14

    	 

    

 

PUBCO/CELL SOURCE,
LTD.

OMNIBUS SIGNATURE
PAGE TO THE SUBSCRIPTION AGREEMENT

AND REGISTRATION RIGHTS AGREEMENT

 

Subscriber hereby elects to subscribe
under the Subscription Agreement for a total of  ________ Units at a price of $0.75 per Unit (NOTE: to be completed by subscriber)
and executes the Subscription Agreement and the Registration Rights Agreement.

 

Date (NOTE: To be completed by subscriber):
 _________________________

_________________________________________________________________________________________________

 

If the Purchaser is an INDIVIDUAL, and
if purchased as JOINT TENANTS, as TENANTS IN COMMON, or as COMMUNITY PROPERTY:

	 	 	 	 	 
	 	Print Name(s)	 	Social Security Number(s)	 
	 	 	 	 	 
	 	 	 	 	 
	 	Signature(s) of Subscriber(s)	 	Signature	 
	 	 	 	 	 
	 	 	 	 	 
	 	Date	 	Address	 

 

If the Purchaser is a PARTNERSHIP, CORPORATION, LIMITED LIABILITY
COMPANY or TRUST:

 

	 	 	 	 	 
	 	Name of Partnership, Corporation, Limited Liability Company or Trust	 	Federal Taxpayer Identification Number 	 
	 	 	 	 	 
	 	By:	 	 	 	 
	 	 	Name:	 	State of Organization	 
	 	 	Title:	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	Date	 	Address	 
	 	 	 	 	 
	 	CELL SOURCE, LTD.	 	 	 
	 	 	 	 	 
	 	By:	 	 	 	 
	 	 	Authorized Officer	 	 	 

 

    	A-15

    	 

    

 

PUBCO/CELL SOURCE,
LTD. ACCREDITED

 

INVESTOR CERTIFICATION—UNITED STATES 

 

RESIDENTS

 

For Individual Investors Only

(all Individual Investors must INITIAL
where appropriate):

 

	Initial _______	 	I have an individual net worth, or joint net worth with my spouse, as of the date hereof (excluding, for the purpose of net worth calculation, the value of such person’s or persons’ primary residence, after deducting any mortgage securing such primary residence) in excess of $1 million.
	 	 	 
	Initial _______	 	I have had an annual gross income for the past two years of at least $200,000 (or $300,000 jointly with my spouse) and expect my income (or joint income, as appropriate) to reach the same level in the current year.
	 	 	 
	Initial _______	 	I am a director or executive officer of Pubco.

 

For Non-Individual Investors

(all Non-Individual Investors must INITIAL
where appropriate):

 

	Initial _______	 	The investor certifies that it is a partnership, corporation, limited liability company or business trust that is 100% owned by persons who meet at least one of the criteria for Individual Investors set forth above.
	 	 	 
	Initial _______	 	The investor certifies that it is a partnership, corporation, limited liability company or any organization described in Section 501(c)(3) of the Internal Revenue Code, Massachusetts or similar business trust that has total assets of at least $5 million and was not formed for the purpose of investing the Company.
	 	 	 
	Initial _______	 	The investor certifies that it is an employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974, whose investment decision is made by a plan fiduciary (as defined in ERISA §3(21)) that is a bank,   savings   and   loan   association,  insurance  company   or   registered investment adviser.
	 	 	 
	Initial _______	 	The investor certifies that it is an employee benefit plan whose total assets exceed $5,000,000 as of the date of this Agreement.
	 	 	 
	Initial _______	 	The undersigned certifies that it is a self-directed employee benefit plan whose investment decisions are made solely by persons who meet either of the criteria for Individual Investors.

 

    	A-16

    	 

    

 

	
        Initial _______
	 	The investor certifies that it is a U.S. bank, U.S. savings and loan association or other similar U.S. institution acting in its individual or fiduciary capacity.
	 	 	 
	Initial _______	 	The undersigned certifies that it is a broker-dealer registered pursuant to §15 of the Securities Exchange Act of 1934.
	 	 	 
	Initial _______	 	The investor certifies that it is an organization described in §501(c)(3) of the Internal Revenue Code with total assets exceeding $5,000,000 and not formed for the specific purpose of investing in the Company.
	 	 	 
	Initial _______	 	The investor certifies that it is a trust with total assets of at least $5,000,000, not formed for the specific purpose of investing in the Company, and whose purchase is directed by a person with such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of the prospective investment.
	 	 	 
	Initial _______	 	The investor certifies that it is a plan established and maintained by a state or its political subdivisions, or any agency or instrumentality thereof, for the benefit of its employees, and which has total assets in excess of $5,000,000.
	 	 	 
	Initial _______	 	The investor certifies that it is an insurance company as defined in §2(13) of the Securities Act, or a registered investment company.
	 	 	 
	Initial _______	 	An investment company registered under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of that Act.
	 	 	 
	Initial _______	 	A Small Business Investment Company licensed by the U.S.  Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958.
	 	 	 
	Initial _______	 	A private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940.

 

    	A-17

    	 

    

 

Representations and Warranties of the
Purchaser (for Canadian Residents)

 

1.          The
Purchaser (on its own behalf and, if applicable, on behalf of the Disclosed Beneficial Purchaser) represents, warrants and covenants
to the Company that:

 

(a)          unless
the Purchaser is purchasing the Units under Section 00, the Purchaser is (x) purchasing the Units as principal for his,
her or its own account, and not for the benefit of any other person, and for investment purposes only, and not with a view to the
resale or distribution of all or any of the Units, (y) the Purchaser is resident in or otherwise subject to the applicable
securities legislation of the jurisdiction set out as the “Purchaser’s Address” on the face page hereof and (z)
the Purchaser satisfies one or more of the following criteria:

 

(i)           the
Purchaser is an “accredited investor” as such term is defined in National Instrument 45-106 – Prospectus and
Registration Exemptions (“NI 45-106”), was not created or used solely to purchase or hold securities as
an accredited investor, and has indicated each category of “accredited investor” the Purchaser satisfies by completing
the Accredited Investor Certificate attached to this Subscription Agreement; OR

 

(ii)          the
Purchaser is resident in or otherwise subject to applicable securities legislation of British Columbia, Alberta, Manitoba, Québec,
New Brunswick, Nova Scotia, Prince Edward Island or Newfoundland and Labrador and is one of the following and has so indicated
by initialling the applicable paragraph:

 

		_____	a “director”, “executive officer” or “control person” of the
Company, or of an affiliate of the Company (within the meaning of these expressions as used in NI 45-106);

 

		_____	a “spouse” (within the meaning of that expression as used in NI 45-106), parent, grandparent,
brother, sister or child of any person referred to in subparagraph (A) above;

 

		_____	a parent, grandparent, brother, sister or child of the spouse of any person referred to in subparagraph
(A) above;

 

		_____	a “close personal friend” (within the meaning of that expression as used in NI 45-106)
of any person referred to in subparagraph (A) above and, if requested by the Company on behalf of the Company, will provide a signed
statement describing any such persons;

 

    	A-18

    	 

    

 

		_____	a “close business associate” (within the meaning of that expression as used in NI 45-106)
of any person referred to in subparagraph (A) above and, if requested by the Company on behalf of the Company, will provide a signed
statement describing any of such persons;

 

		_____	a “founder” (within the meaning of that expression as used in NI 45-106) of the Company
or a spouse, parent, grandparent, brother, sister, child, close personal friend or close business associate of a founder of the
Company;

 

		_____	a parent, grandparent, brother, sister or child of a spouse of a founder of the Company;

 

		_____	a “person” (within the meaning of that expression as used in NI 45-106) of which a
majority of the voting securities are beneficially owned by, or a majority of directors are, persons or companies described in
subparagraphs (A) through (G) above; or

 

		_____	a trust or estate of which all of the beneficiaries or a majority of the trustees or executors
are persons or companies described in subparagraphs (A) through (G) above;

 

(b)          if
the Purchaser is not purchasing the Units as a principal, the Purchaser is duly authorized to enter into this Subscription Agreement
and to execute and deliver all documentation in connection with the purchase of the Units on behalf of the Disclosed Beneficial
Purchaser and (x) the Purchaser and the Disclosed Beneficial Purchaser acknowledge that the Company is required by law to
disclose to certain regulatory authorities the identity of the Disclosed Beneficial Purchaser for whom it may be acting, (y)
the Purchaser is resident in the jurisdiction set out as the “Purchaser’s Address” on the face page hereof and
the Disclosed Beneficial Purchaser is resident in the jurisdiction set out under the heading “Disclosed Beneficial Purchaser
Information” on the face page hereof and (z) either:

 

(i)           the
Disclosed Beneficial Purchaser is (x) purchasing the Units as principal for his, her or its own account and not for the
benefit of any other person, (y) purchasing the Units for investment only and not with a view to the resale or distribution
of all or any of the Units and (z) is an “accredited investor” as such term is defined in NI 45-106, was not
created or used solely to purchase or hold securities as an accredited investor, and has indicated each category of “accredited
investor” that the Disclosed Beneficial Purchaser satisfies by completing the Accredited Investor Certificate attached to
this Subscription Agreement; OR

 

    	A-19

    	 

    

 

(ii)          the
Purchaser is an “accredited investor” as such term is defined in paragraphs (p) or (q) of the definition of “accredited
investor” in NI 45-106 (provided, however, that it is not a trust company or trust corporation registered under
the laws of Prince Edward Island that is not registered or authorized under the Trust and Loan Companies Act (Canada) or
under comparable legislation in another jurisdiction in Canada) and has indicated that the Purchaser satisfies one of the categories
of “accredited investor” set out in paragraphs (p) or (q) of “accredited investor” by completing the Accredited
Investor Certificate attached to this Subscription Agreement as Schedule “C”;

 

(c)          neither
the Purchaser nor, if applicable, the Disclosed Beneficial Purchaser was formed for the purpose of purchasing the Units;

 

(d)          if
the Purchaser is an individual, the Purchaser has the legal capacity and competence to enter into and execute this Subscription
Agreement and to take all actions required pursuant hereto;

 

(e)          no
Units were offered to the Purchaser (or, if applicable, the Disclosed Beneficial Purchaser) by means of general solicitation or
advertisement and, in connection therewith, the Purchaser (and, if applicable, the Disclosed Beneficial Purchaser) has not become
aware of any advertisement in printed media of general and regular paid circulation (or other printed public media), radio, television
or telecommunications or other form of advertisement with respect to the distribution of the Units;

 

(f)          the
Purchaser (and, if applicable, the Disclosed Beneficial Purchaser) acknowledges and consents to the placement of any required legend
under Canadian securities laws on any certificate evidencing the Securities issued to the Purchaser;

 

(g)          the
Purchaser (and, if applicable, the Disclosed Beneficial Purchaser) acknowledges that purchasing, holding, exercising and disposing
of the Securities may have tax consequences under the laws of Canada, the United States or other jurisdictions, prospective purchasers
are solely responsible for determining the tax consequences applicable to their particular circumstances and that he, she or it
has been advised by the Company to consult its tax advisors concerning an investment in the Units;

 

2.            The
Purchaser agrees (on its own behalf and, if applicable, on behalf of the Disclosed Beneficial Purchaser) that the representations
and warranties of the Purchaser (and, if applicable, the Disclosed Beneficial Purchaser) will be true and correct both as of the
execution of this Subscription Agreement and as of the Closing Time and that the representations and warranties of the Purchaser
(and, if applicable, the Disclosed Beneficial Purchaser) in this Subscription Agreement will survive the Closing Time and are made
by the Purchaser (on its own behalf and, if applicable, on behalf of the Disclosed Beneficial Purchaser) with the intention that
they be relied upon by the Company in determining the eligibility of a purchaser of Units under the Offering. The Purchaser (and,
if applicable, the Disclosed Beneficial Purchaser) agrees to indemnify and save harmless the Company and its shareholders, directors,
officers, employees, counsel and agents against all losses, claims, costs, expenses and damages or liabilities which any of them
may suffer or incur which are caused or arise from a breach thereof. The Purchaser undertakes to immediately notify the Company
of any change in any statement or other information relating to the Purchaser (or, if applicable, the Disclosed Beneficial Purchaser)
set forth herein which takes place prior to the Closing Time.

 

    	A-20

    	 

    

  

3.            The
Purchaser (on its own behalf and, if applicable, on behalf of the Disclosed Beneficial Purchaser) acknowledges that this Subscription
Agreement and the schedules hereto require the Purchaser to provide certain personal information relating to the Purchaser (and,
if applicable, the Disclosed Beneficial Purchaser) to the Company. Such information is being collected by the Company for the purposes
of completing the Offering, which includes, without limitation, determining the Purchaser’s eligibility to purchase the Units
under applicable securities legislation, preparing and registering certificates representing the Securities to be issued to the
Purchaser and completing filings required by any securities regulatory authority. Such personal information may be disclosed by
the Company to (a) securities regulatory authorities, (b) any government agency, board or other entity and (c) any of the other
parties involved in this private placement, including the Company and its legal counsel, and may be included in record books in
connection with this Offering. By executing this Subscription Agreement, the Purchaser (on its own behalf and, if applicable, on
behalf of the Disclosed Beneficial Purchaser) is deemed to be consenting to the foregoing collection, use and disclosure of such
personal information. The Purchaser (on its own behalf and, if applicable, on behalf of the Disclosed Beneficial Purchaser) also
consents to the filing of copies or originals of any of the schedules to this Subscription Agreement as may be required to be filed
with any securities regulatory authority in connection with the transactions contemplated hereby.

 

4.            The
Purchaser (on its own behalf and, if applicable, on behalf of the Disclosed Beneficial Purchaser) represents and warrants that
the Aggregate Subscription Price which will be advanced by the Purchaser to the Company hereunder will not represent proceeds of
crime for the purposes of the Proceeds of Crime (Money Laundering) and Terrorist Financing Act (Canada) (the “PCMLA”)
and the Purchaser acknowledges (on its own behalf and, if applicable, on behalf of the Disclosed Beneficial Purchaser) that the
Company may in the future be required by law to disclose his, her or its name and other information relating to this Subscription
Agreement and his, her or its subscription hereunder, on a confidential basis, pursuant to the PCMLA or other applicable legislation.
To the best of his, her or its knowledge, none of the subscription funds to be provided pursuant to this Subscription Agreement
(a) have been or will be derived from or related to any activity that is deemed criminal under the law of Canada, the United States
of America or any other jurisdiction or (b) are being tendered on behalf of a person or entity who has not been identified to the
Purchaser. The Purchaser shall promptly notify the Company if the Purchaser discovers that any of such representations ceases to
be true, and to provide the Company with appropriate information in connection therewith.

 

    	A-21

    	 

    

 

ACCREDITED INVESTOR CERTIFICATE (for
Canadian residents)

 

PLEASE MARK YOUR INITIALS BESIDE THE
CATEGORY OF “ACCREDITED INVESTOR” TO WHICH YOU BELONG.

 

Accredited Investor (defined in National
Instrument 45-106) means:

 

	_______	 	(a)	a Canadian financial institution, or a Schedule III bank;
	 	 	 	 
	_______	 	(b)	the Business Development Bank of Canada incorporated under the Business Development Bank of Canada Act (Canada);
	 	 	 	 
	_______	 	(c)	a subsidiary of any person referred to in paragraphs (a) or (b), if the person owns all of the voting securities of the subsidiary, except the voting securities required by law to be owned by directors of that subsidiary;
	 	 	 	 
	_______	 	(d)	a person registered under the securities legislation of a jurisdiction of Canada as an adviser or dealer, other than a person registered solely as a limited market dealer under one or both of the Securities Act (Ontario) or the Securities Act (Newfoundland and Labrador);
	 	 	 	 
	_______	 	(e)	an individual registered or formerly registered under the securities legislation of a jurisdiction of Canada as a representative of a person referred to in paragraph (d);
	 	 	 	 
	_______	 	(f)	the Government of Canada or a jurisdiction of Canada, or any crown corporation, agency or wholly owned entity of the Government of Canada or a jurisdiction of Canada;
	 	 	 	 
	_______	 	(g)	a municipality, public board or commission in Canada and a metropolitan community, school board, the Comité de gestion de la taxe scolaire de l’île de Montréal or an intermunicipal management board in Québec;
	 	 	 	 
	_______	 	(h)	any national, federal, state, provincial, territorial or municipal government of or in any foreign jurisdiction, or any agency of that government;
	 	 	 	 
	_______	 	(i)	a pension fund that is regulated by either the Office of the Superintendent of Financial Institutions (Canada) or a pension commission or similar regulatory authority of a jurisdiction of Canada;
	 	 	 	 
	_______	 	(j)	an individual who, either alone or with a spouse, beneficially owns, directly or indirectly, financial assets having an aggregate realizable value that before taxes, but net of any related liabilities, exceeds $1,000,000;
	 	 	 	 
	_______	 	(k)	an individual whose net income before taxes exceeded $200,000 in each of the two most recent calendar years or whose net income before taxes combined with that of a spouse exceeded $300,000 in each of the two most recent calendar years and who, in either case, reasonably expects to exceed that net income level in the current calendar year;

 

    	A-22

    	 

    

  

(Note: If individual accredited investors
wish to purchase through wholly-owned holding companies or similar entities, such purchasing entities must qualify under paragraph
(t) below, which must be initialled)

 

	_______	 	(l)	an individual who, either alone or with a spouse, has net assets of at least $5,000,000;
	 	 	 	 
	_______	 	(m)	a person, other than an individual or investment fund, that has net assets of at least $5,000,000 as shown on its most recently prepared financial statements, provided that such person has not been created or used solely to purchase or hold securities as an accredited investor;  
	 	 	 	 
	_______	 	(n)	an investment fund that distributes or has distributed its securities only to

 

(A)         a
person that is or was an accredited investor at the time of the distribution,

 

(B)          a
person that acquires or acquired securities in the circumstances referred to in sections 2.10 [Minimum amount investment],
and 2.19 [Additional investment in investment funds] of NI 45-106, or

 

(C)          a
person described in paragraph (A) or (B) that acquires or acquired securities under section 2.18 [Investment fund reinvestment]
of NI 45-106;

 

	_______	 	(o)	an investment fund that distributes or has distributed securities under a prospectus in a jurisdiction of Canada for which the regulator or, in Québec, the securities regulatory authority, has issued a receipt;
	 	 	 	 
	_______	 	(p)	a trust company or trust corporation registered or authorized to carry on business under the Trust and Loan Companies Act (Canada) or under comparable legislation in a jurisdiction of Canada or a foreign jurisdiction, acting on behalf of a fully managed account managed by the trust company or trust corporation, as the case may be;
	 	 	 	 
	_______	 	(q)	a person acting on behalf of a fully managed account managed by that person, if that person

 

(A)          is
registered or authorized to carry on business as an adviser or the equivalent under the securities legislation of a jurisdiction
of Canada or a foreign jurisdiction, and

 

(B)           in
Ontario, is purchasing a security that is not a security of an investment fund;

 

    	A-23

    	 

    

 

	_______	 	(r)	a registered charity under the Income Tax Act (Canada) that, in regard to the trade, has obtained advice from an eligibility adviser or an adviser registered under the securities legislation of the jurisdiction of the registered charity to give advice on the securities being traded;
	 	 	 	 
	_______	 	(s)	an entity organized in a foreign jurisdiction that is analogous to any of the entities referred to in paragraphs (a) to (d) or paragraph (i) in form and function;
	 	 	 	 
	_______	 	(t)	a person in respect of which all of the owners of interests, direct, indirect or beneficial, except the voting securities required by law to be owned by directors, are persons that are accredited investors (as defined in NI 45-106);
	 	 	 	 
	_______	 	(u)	an investment fund that is advised by a person registered as an adviser or a person that is exempt from registration as an adviser; or
	 	 	 	 
	_______	 	(v)	a person that is recognized or designated by the securities regulatory authority or, except in Ontario and Québec, the regulator as

 

(A)         an
accredited investor, or

 

(B)         an
exempt purchaser in Alberta or British Columbia, and confirmation of such status is being provided to the Company and the Agents.

 

NOTE: The investor must initial beside
the applicable portion of the above definition.

 

Dated:  _____________

 

	If a Corporation, Partnership or Other Entity:	 	If an Individual:
	 	 	 
	Name of Entity	 	Signature
	 	 	 
	Type of Entity 	 	Printed or Typed Name
	 	 	 
	Signature of Person Signing	 	 
	 	 	 
	Printed or Typed Name and Title of Person Signing	 	 

 

    	A-24

    	 

    

  

PUBCO/CELL SOURCE,
LTD.

Investor Profile

(Must be completed by Investor)

Section A - Personal Investor Information

 

Investor Name(s): __________________________________________________________________________________

Individual executing Profile or Trustee: ________________________________________________________________

Social Security Numbers / Federal I.D. Number: __________________________________________________________

 

	Date of Birth:	______________	Marital Status:  ________________________________
	Joint Party Date of Birth: 	______________	Investment Experience (Years): ____________________
	Annual Income:	______________	Liquid Net Worth:  ______________________________
	Net Worth (excluding value of primary
    residence):  ______	 

Tax Bracket:                           ___________
15% or below        ________ 25% - 27.5%        _______Over
27.5%

	Investment Objectives (circle one or more):	Preservation of Capital, Income, Capital Appreciation, Trading Profits, Speculation or Other (please specify) * See definitions on following page

	Home Street Address: 	 	 
	Home City, State & Zip Code: 	 	 
	Home Phone: ________________	Home Fax: ________________________	Home Email: ____________________
	Employer: 	 	 
	Employer Street Address: 	 	 
	Employer City, State & Zip Code: 	 	 
	Bus. Phone: ________________	Bus. Fax: _________________________	Bus. Email: _____________________
	Type of Business:	 	 

  

If you are a United States citizen, please list
the number and jurisdiction of issuance of any other government-issued document evidencing residence and bearing a photograph or
similar safeguard (such as a driver’s license or passport), and provide a photocopy of each of the documents
you have listed.

_______________________________________________________________________________________________

If you are NOT a United
States citizen, for each jurisdiction of which you are a citizen or in which you work or reside, please list (i) your passport
number and country of issuance or (ii) alien identification card number AND (iii) number and country of issuance of any
other government-issued document evidencing nationality or residence and bearing a photograph or similar safeguard, and provide
a photocopy of each of these documents you have listed. These photocopies must be certified by a lawyer as to authenticity.

_______________________________________________________________________________________________

 

Section B – Securities Delivery Instructions

 

_____ Please deliver securities to the Employer Address listed
in Section A.

_____ Please deliver securities to the Home Address listed in
Section A.

_____ Please deliver securities to the following address:

           _____________________________________________________.

 

Section C – Form of Payment
– Check or Wire Transfer

 

_____ Check payable to Signature Bank, As Escrow Agent for
Cell Source, Ltd.

_____ Wire funds from my outside account according to the “Instructions”
Page.

_____ The funds for this investment are rolled over, tax deferred
from _________ within the allowed 60 day window.

  

Please check if you are a FINRA member or affiliate of a FINRA
member firm:  ________

 

	 	 	 
	Investor Signature	 	Date
	 	 	 
	 	 	 
	Investor Signature	 	Date

  

    	A-25

    	 

    

 

Investment Objectives: The typical
investment listed with each objective are only some examples of the kinds of investments that have historically been consistent
with the listed objectives. Cell Source, Ltd. can assure that any investment will achieve your intended objective. You must make
your own investment decisions and determine for yourself if the investments you select are appropriate and consistent with your
investment objectives.

 

Cell Source, Ltd. does not assume responsibility
to you for determining if the investments you selected are suitable for you.

 

Preservation of Capital: An investment
objective of Preservation of Capital indicates you seek to maintain the principal value of your investments and are interested
in investments that have historically demonstrated a very low degree of risk of loss of principal value. Some examples of typical
investments might include money market funds and high quality, short-term fixed income products.

 

Income: An investment objective
of Income indicates you seek to generate income from investments and are interested in investments that have historically
demonstrated a low degree of risk of loss of principal value. Some examples of typical investments might include high quality,
short and medium-term fixed income products, short-term bond funds and covered call options.

 

Capital Appreciation: An investment
objective of Capital Appreciation indicates you seek to grow the principal value of your investments over time and are willing
to invest in securities that have historically demonstrated a moderate to above average degree of risk of loss of principal value
to pursue this objective. Some examples of typical investments might include Ordinary Sharess, lower quality, medium- term fixed
income products, equity mutual funds and index funds.

 

Trading Profits: An investment objective
of Trading Profits indicates you seek to take advantage of short-term trading opportunities, which may involve establishing
and liquidating positions quickly. Some examples of typical investments might include short-term purchases and sales of volatile
or low priced Ordinary Sharess, put or call options, spreads, straddles and/or combinations on equities or indexes. This is a high-risk
strategy.

 

Speculation: An investment objective
of Speculation indicates you seek a significant increase in the principal value of your investments and are willing to accept
a corresponding greater degree of risk by investing in securities that have historically demonstrated a high degree of risk of
loss of principal value to pursue this objective. Some examples of typical investments might include lower quality, long-term fixed
income products, initial public offerings, volatile or low priced Ordinary Shares, the purchase of sale of put or call options,
spreads, straddles and/or combinations on equities or indexes, and the use of short- term or day trading strategies.

 

Other: Please specify.

 

    	A-26

    	 

    

 

[This page left intentionally
blank]REGISTRATION RIGHTS AGREEMENT

 

This Registration Rights Agreement (this
“Agreement”) is made and entered into effective as of [insert], 201_, (the “Effective Date”) between Cell
Source, Ltd., an Israeli corporation (the “Company”), and the persons who have executed the signature page(s) hereto
(each, a “Purchaser” and collectively, the “Purchasers”).

 

RECITALS:

 

WHEREAS, the Company
is obligated to enter, subject to the sale of the Maximum Offering Amount, the Acquisition pursuant to which Cell Source will become
a wholly-owned subsidiary of a publicly traded company (the “Pubco” and, as context may require, when referring to
Pubco after the consummation of the Acquisition, the “Company”);

 

WHEREAS, prior to the
Acquisition and to provide the capital required by the Company for working capital and other purposes, the Company has offered
in compliance with Rule 506 of Regulation D of the Securities Act (as defined herein), to investors in a private placement transaction
(the “PPO”), units (“Units”) of its securities, each Unit consisting of one share of Ordinary Shares (the
“Investor Shares”) and Ordinary Shares purchase warrants (the “Investor Warrants”) to purchase one Ordinary
Share at an exercise price of $0.75;

 

WHEREAS, in connection
with the Acquisition and the PPO, the Company agrees to provide certain registration rights related to the Investor Shares and
the shares of Ordinary Shares issuable upon exercise of the Investor Warrants, on the terms set forth herein;

 

NOW, THEREFORE, in
consideration of the mutual promises, representations, warranties, covenants, and conditions set forth herein, the parties mutually
agree as follows:

 

1.        Certain
Definitions. As used in this Agreement, the following terms shall have the following respective meanings:

 

“Approved Market” means the Over-the-Counter
Bulletin Board, the OTC Markets, the Nasdaq Stock Market, the New York Stock Exchange or the NYSE MKT.

 

“Acquisition” has the
same meaning as defined in the Subscription Agreement.

 

“Blackout Period”
means, with respect to a registration, a period, in each case commencing on the day immediately after the Company notifies the
Purchasers that they are required, because of the occurrence of an event of the kind described in Section 4(f) hereof, to suspend
offers and sales of Registrable Securities during which the Company, in the good faith judgment of its Board of Directors, determines
(because of the existence of, or in anticipation of, any acquisition, financing activity, or other transaction involving the Company,
or the unavailability for reasons beyond the Company’s control of any required financial statements, disclosure of information
which is in its best interest not to publicly disclose, or any other event or condition of similar significance to the Company)
that the registration and distribution of the Registrable Securities to be covered by such Registration Statement, if any, would
be seriously detrimental to the Company and its stockholders and ending on the earlier of (1) the date upon which the material
non-public information commencing the Blackout Period is disclosed to the public or ceases to be material and (2) such time as
the Company notifies the selling Holders that the Company will no longer delay such filing of the Registration Statement, recommence
taking steps to make such Registration Statement effective, or allow sales pursuant to such Registration Statement to resume.

 

    	C-1

    	 

    

 

“Business
Day” means any day of the year, other than a Saturday, Sunday, or other day on which the Commission is required or authorized
to close.

 

“Commission”
means the U. S. Securities and Exchange Commission or any other federal agency at the time administering the Securities Act.

 

“Ordinary
Shares” means the Ordinary Shares, each of nominal value of NIS 0.01, of the Company and any and all shares of capital
stock or other equity securities of: (i) the Company which are added to or exchanged or substituted for the Ordinary Shares by
reason of the declaration of any stock dividend or stock split, the issuance of any distribution or the reclassification, readjustment,
recapitalization or other such modification of the capital structure of the Company; and (ii) any other corporation, now or hereafter
organized under the laws of any state or other governmental authority, with which the Company is merged, which results from any
consolidation or reorganization to which the Company is a party, or to which is sold all or substantially all of the shares or
assets of the Company, if immediately after such merger, consolidation, reorganization or sale, the Company or the stockholders
of the Company own equity securities having in the aggregate more than 50% of the total voting power of such other corporation,
including the Acquisition.

 

“Effective Date” has
the meaning given it in the preamble to this Agreement.

 

“Exchange Act” means
the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission promulgated thereunder.

 

“Family Member”
means (a) with respect to any individual, such individual’s spouse, any descendants (whether natural or adopted), any trust
all of the beneficial interests of which are owned by any of such individuals or by any of such individuals together with any organization
described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, the estate of any such individual, and any corporation,
association, partnership or limited liability company all of the equity interests of which are owned by those above described individuals,
trusts or organizations and (b) with respect to any trust, the owners of the beneficial interests of such trust.

 

“Holder”
means each Purchaser or any of such Purchaser’s respective successors and Permitted Assignees who acquire rights in accordance
with this Agreement with respect to any Registrable Securities directly or indirectly from a Purchaser or from any Permitted Assignee.

 

“Initial Registration
Statement” means the initial Registration Statement filed pursuant to this Agreement.

 

“Investor Shares” has
the meaning given it in the recitals of this Agreement.

 

“Investor Warrants” has
the meaning given it in the recitals of this Agreement.

 

    	C-2

    	 

    

 

“Majority Holders” means
at any time Holders representing a majority of the Investor Shares and the Investor Warrants.

 

“Maximum Offering Amount”
has the same meaning as defined in the Subscription Agreement.

 

“Permitted
Assignee” means (a) with respect to a partnership, its partners or former partners in accordance with their partnership
interests, (b) with respect to a corporation, its stockholders in accordance with their interest in the corporation, (c) with respect
to a limited liability company, its members or former members in accordance with their interest in the limited liability company,
(d) with respect to an individual party, any Family Member of such party, (e) an entity that is controlled by, controls, or is
under common control with a transferor, or (f) a party to this Agreement.

 

The terms “register,”
“registered,” and “registration” refer to a registration effected by preparing and filing
a registration statement in compliance with the Securities Act, and the declaration or ordering of the effectiveness of such registration
statement.

 

“Registrable
Securities” means the Investor Shares and the Registrable Warrant Shares but excluding (i) any Registrable Securities
that have been publicly sold without registration under the Securities Act either pursuant to Rule 144 of the Securities Act or
otherwise, or that are eligible to be sold without restriction under Rule 144 of the Securities Act; or (ii) any Registrable Securities
sold by a person in a transaction pursuant to a registration statement filed under the Securities Act.

 

“Registrable
Warrant Shares” means the shares of Ordinary Shares issued or issuable to each Purchaser upon exercise of the Investor
Warrants.

 

“Registration Default Date”
means the date that is 120 days after the Registration Filing Date.

 

“Registration Default Period”
means the period following the Registration Filing Date or the Registration Default Date, as applicable, during which any Registration
Event occurs and is continuing.

 

“Registration Event”
means the occurrence of any of the following events:

 

(a)         the
Company fails to file with the Commission the Registration Statement on or before the Registration Filing Date;

 

(b)         the
Registration Statement is not declared effective by the Commission on or before the Registration Default Date;

 

(c)         after
the SEC Effective Date, sales cannot be made pursuant to the Registration Statement for any reason (including without limitation
by reason of a stop order, or the Company’s failure to update the Registration Statement) except as excused pursuant to Section
3(e); or

 

    	C-3

    	 

    

 

(d)         the
Ordinary Shares generally or the Registrable Securities specifically are not listed or included for quotation on an Approved Market,
or trading of the Ordinary Shares is suspended or halted on the Approved Market, which at the time constitutes the principal market
for the Ordinary Shares, for more than two full, consecutive Trading Days; provided, however, a Registration Event
shall not be deemed to occur if all or substantially all trading in equity securities (including the Ordinary Shares) is suspended
or halted on the Approved Market for any length of time.

 

“Registration
Filing Date” means the date that is 120 days after the date on which the Company closes on the sale of the Maximum Offering
Amount.

 

“Registration
Statement” means the registration statement that the Company is required to file pursuant to this Agreement to register
the Registrable Securities.

 

“Rule 144” means Rule 144 promulgated by
the Commission under the Securities Act.

 

“Rule 415”
means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or
any similar rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as such Rule.

 

“Securities
Act” means the Securities Act of 1933, as amended, or any similar federal statute promulgated in replacement thereof,
and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time.

 

“SEC Effective
Date” means the date the Registration Statement is declared effective by the Commission.

 

“Subscription
Agreement” means the subscription agreement attached to the Confidential Private Placement Memorandum of the Company
dated November 13, 2013, as the same may be amended and supplemented from time to time.

 

“Trading Day”
means (a) if the Ordinary Shares is listed or quoted on an Approved Market, then any day during which securities are generally
eligible for trading on the Approved Market, or (b) if the Ordinary Shares is not then listed or quoted and traded on an Approved
Market, then any business day.

 

		2.	Registration.

 

(a)         Registration
on Form S-1. Subject to the closing on the sale of the Maximum Offering Amount and the consummation of the Acquisition, no
later than the Registration Filing Date, the Company shall file with the Commission a Registration Statement on Form S-1, or other
applicable form, relating to the resale by the Holders of all of the Registrable Securities, and the Company shall use its commercially
reasonably efforts to cause such Registration Statement to be declared effective prior to the Registration Default Date. For the
avoidance of doubt, the Registration Statement may include such other securities as determined by the Company.

 

    	C-4

    	 

    

 

(b)       Occurrence
of Registration Event. If a Registration Event occurs, then the Company will issue, for each 30 day period the Registration
Event is not cured, to each Holder of Registrable Securities (a “Qualified Purchaser”), as liquidated damages
for the amount of damages to the Qualified Purchaser by reason thereof, such number of Ordinary Shares that would result in the
effective purchase price of the Units purchased pursuant to the Securities Purchase Agreement to be equal $0.10 less than the original
purchase price of the Unit, provided that the effective price shall not be lower than $.25 per Unit and provided, however,
if a Registration Event occurs (or is continuing) on a date more than one-year after the Company filed a Current Report on Form
8-K relating to the Acquisition and the PPO and providing Form 10 information with respect thereto, liquidated damages shall be
paid only with respect to that portion of the Qualified Purchaser’s Registrable Securities that cannot then be immediately
resold in reliance on Rule 144. The Registration Default Period shall terminate upon (i) the filing of the Registration Statement
in the case of clause (a) of the definition of Registration Event, (ii) the SEC Effective Date in the case of clause (b) of the
definition of Registration Event, (iii) the ability of the Qualified Purchaser to effect sales pursuant to the Registration Statement
in the case of clause (c) of the definition of Registration Event, and (iv) the listing or inclusion and/or trading of the Ordinary
Shares on an Approved Market, as the case may be, in the case of clause (d) of the definition of Registration Event. The amounts
payable as liquidated damages pursuant to this Section 2(b) shall be issued in fully-paid, non-assessable restricted Ordinary Shares.

 

(c)         Notwithstanding
the provisions of Section 2(b) above, (a) if the Commission does not declare the Registration Statement effective on or before
the Registration Default Date, or (b) if the Commission allows the Registration Statement to be declared effective at any time
before or after the Registration Default Date, subject to the withdrawal of certain Registrable Securities from the Registration
Statement, and the reason for (a) or (b) is the Commission’s determination that (x) the offering of any of the Registrable
Securities constitutes a primary offering of securities by the Company, (y) Rule 415 may not be relied upon for the registration
of the resale of any or all of the Registrable Securities, and/or (z) a Holder of any Registrable Securities must be named as an
underwriter, the Holders understand and agree that in the case of (b) the Company may reduce, on a pro rata basis, the total
number of Registrable Securities to be registered on behalf of each such Holder, and, in the case of (a) or (b), that a Holder
shall not be entitled to any liquidated damages with respect to the Registrable Securities not registered for the reason set forth
in (a), or so reduced on a pro rata basis as set forth in (b). In any such pro rata reduction, the number of Registrable
Securities to be registered on such Registration Statement will first be reduced by the Registrable Securities represented by the
Registrable Warrant Shares (applied, in the case that some Registrable Warrant Shares may be registered, to the Holders on a pro
rata basis based on the total number of unregistered Registrable Warrant Shares held by such Holders on a fully diluted basis),
and second by Registrable Securities represented by Investor Shares (applied, in the case that some Investor Shares may be registered,
to the Holders on a pro rata basis based on the total number of unregistered Investor Shares held by such Holders).
Any Registrable Securities not included in the Initial Registration Statement shall be included in
a subsequent Registration Statement the Company will file no later than six months after the prior Registration Statement (or such
other period as permitted under the Securities Act and applicable Commission rules and regulations). The Holders acknowledge and
agree the provisions of this paragraph may apply to more than one Registration Statement.

 

    	C-5

    	 

    

 

3.            Registration
Procedures for Registrable Securities. The Company will keep each Holder reasonably advised as to the filing and effectiveness
of the Registration Statement. At its expense with respect to the Registration Statement, the Company will:

 

(a)         prepare
and file with the Commission with respect to the Registrable Securities, a Registration Statement on Form S-1, or any other form
for which the Company then qualifies or which counsel for the Company shall deem appropriate and which form shall be available
for the sale of the Registrable Securities in accordance with the intended methods of distribution thereof, and use its commercially
reasonable efforts to cause such Registration Statement to become effective and shall remain effective until the Investor Warrants
are no longer outstanding or for such shorter period ending on the earlier to occur of (i) the date as of which all of the Holders
as selling stockholders thereunder may sell all of the Registrable Securities registered for resale thereon without restriction
pursuant to Rule 144 (or any successor rule thereto) promulgated under the Securities Act or (ii) the date when all of the Registrable
Securities registered thereunder have been sold (the “Effectiveness Period”). Thereafter, the Company shall
be entitled to withdraw such Registration Statement and the Investors shall have no further right to offer or sell any of the Registrable
Securities registered for resale thereon pursuant to the respective Registration Statement (or any prospectus relating thereto);

 

(b)         if
the Registration Statement is subject to review by the Commission, promptly respond to all comments and diligently pursue resolution
of any comments to the satisfaction of the Commission;

 

(c)         prepare
and file with the Commission such amendments and supplements to such Registration Statement as may be necessary to keep such Registration
Statement effective during the Effectiveness Period;

 

(d)         furnish,
without charge, to each Holder of Registrable Securities covered by such Registration Statement (i) a reasonable number of copies
of such Registration Statement (including any Attachments thereto other than Attachments incorporated by reference), each amendment
and supplement thereto as such Holder may reasonably request, (ii) such number of copies of the prospectus included in such Registration
Statement (including each preliminary prospectus and any other prospectus filed under Rule 424 of the Securities Act) as such Holders
may reasonably request, in conformity with the requirements of the Securities Act, and (iii) such other documents as such Holder
may require to consummate the disposition of the Registrable Securities owned by such Holder, but only during the Effectiveness
Period;

 

(e)         use
its commercially reasonable efforts to register or qualify such registration under such other applicable securities laws of such
jurisdictions as any Holder of Registrable Securities covered by such Registration Statement reasonably requests and as may be
necessary for the marketability of the Registrable Securities (such request to be made by the time the applicable Registration
Statement is deemed effective by the Commission) and do any and all other acts and things necessary to enable such Holder to consummate
the disposition in such jurisdictions of the Registrable Securities owned by such Holder; provided, that the Company shall
not be required to (i) qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify
but for this paragraph, (ii) subject itself to taxation in any such jurisdiction, or (iii) consent to general service of process
in any such jurisdiction.

 

    	C-6

    	 

    

 

(f)         notify
each Holder of Registrable Securities, the disposition of which requires delivery of a prospectus relating thereto under the Securities
Act, of the happening of any event (as promptly as practicable after becoming aware of such event), which comes to the Company’s
attention, that will after the occurrence of such event cause the prospectus included in such Registration Statement, if not amended
or supplemented, to contain an untrue statement of a material fact or an omission to state a material fact required to be stated
therein or necessary to make the statements therein not misleading and the Company shall promptly thereafter prepare and furnish
to such Holder a supplement or amendment to such prospectus (or prepare and file appropriate reports under the Exchange Act) so
that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus shall not contain an untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein
not misleading, unless suspension of the use of such prospectus otherwise is authorized herein or in the event of a Blackout Period,
in which case no supplement or amendment need be furnished (or Exchange Act filing made) until the termination of such suspension
or Blackout Period;

 

(g)         comply,
and continue to comply during the Effectiveness Period, in all material respects with the Securities Act and the Exchange Act and
with all applicable rules and regulations of the Commission with respect to the disposition of all securities covered by such Registration
Statement;

 

(h)         as
promptly as practicable after becoming aware of such event, notify each Holder of Registrable Securities being offered or sold
pursuant to the Registration Statement of the issuance by the Commission of any stop order or other suspension of effectiveness
of the Registration Statement;

 

(i)         use
its commercially reasonable efforts to cause all the Registrable Securities covered by the Registration Statement to be quoted
on the OTC Bulletin Board or such other Approved Market on which securities of the same class or series issued by the Company are
then listed or traded;

 

(j)         provide
a transfer agent and registrar, which may be a single entity, for the shares of Ordinary Shares at all times;

 

(k)         If
requested by the Holders, cooperate with the Holders to facilitate the timely preparation and delivery of certificates representing
Registrable Securities to be delivered to a transferee pursuant to the Registration Statement, which certificates shall be free,
to the extent permitted by applicable law, of all restrictive legends, and to enable such Registrable Securities to be in such
denominations and registered in such names as any such Holders may request;

 

(l)         during
the Effectiveness Period, refrain from bidding for or purchasing any Ordinary Shares or any right to purchase Ordinary Shares or
attempting to induce any person to purchase any such security or right if such bid, purchase or attempt would in any way limit
the right of the Holders to sell Registrable Securities by reason of the limitations set forth in Regulation M of the Exchange
Act; and

 

    	C-7

    	 

    

 

(m)         take
all other reasonable actions necessary to expedite and facilitate the disposition by the Holders of the Registrable Securities
pursuant to the Registration Statement.

 

4.            Suspension
of Offers and Sales. Each Holder agrees that, upon receipt of any notice from the Company of the happening of any event of
the kind described in Section 3(f) hereof or of the commencement of a Blackout Period, such Holder shall discontinue the disposition
of Registrable Securities included in the Registration Statement until such Holder’s receipt of the copies of the supplemented
or amended prospectus contemplated by Section 3(f) hereof or notice of the end of the Blackout Period, and, if so directed
by the Company, such Holder shall deliver to the Company (at the Company’s expense) all copies (including, without limitation,
any and all drafts), other than permanent file copies, then in such Holder’s possession, of the prospectus covering such
Registrable Securities current at the time of receipt of such notice.

 

5.            Registration
Expenses. The Company shall pay all expenses in connection with any registration obligation provided herein, including, without
limitation, all registration, filing, stock exchange fees, printing expenses, all fees and expenses of complying with applicable
securities laws, and the fees and disbursements of counsel for the Company and of its independent accountants; provided,
that, in any registration, each party shall pay for its own underwriting discounts and commissions and transfer taxes. Except
as provided in this Section and Section 8, the Company shall not be responsible for the expenses of any attorney or other advisor
employed by a Holder.

 

6.            Assignment
of Rights. No Holder may assign its rights under this Agreement to any party without the prior written consent of the Company;
provided, however, that any Holder may assign its rights under this Agreement without such consent to a Permitted
Assignee as long as (a) such transfer or assignment is effected in accordance with applicable securities laws; (b) such transferee
or assignee agrees in writing to become subject to the terms of this Agreement; and (c) such Holder notifies the Company in writing
of such transfer or assignment, stating the name and address of the transferee or assignee and identifying the Registrable Securities
with respect to which such rights are being transferred or assigned.

 

7.            Information
by Holder. A Holder with Registrable Securities included in any registration shall furnish to the Company such information
regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as shall be
required in order to comply with any applicable law or regulation in connection with the registration of such Holder’s Registrable
Securities or any qualification or compliance with respect to such Holder’s Registrable Securities and referred to in this
Agreement. A form of Selling Stockholder Questionnaire is attached as Attachment A hereto for such purposes.

 

    	C-8

    	 

    

 

		8.	Indemnification.

 

(a)         In
the event of the offer and sale of Registrable Securities under the Securities Act, the Company shall, and hereby does, indemnify
and hold harmless, to the fullest extent permitted by law, each Holder, its directors, officers, partners, each other person who
participates as an underwriter in the offering or sale of such securities, and each other person, if any, who controls or is under
common control with such Holder or any such underwriter within the meaning of Section 15 of the Securities Act, against any losses,
claims, damages or liabilities, joint or several, and expenses to which the Holder or any such director, officer, partner or underwriter
or controlling person may become subject under the Securities Act, the Exchange Act, or any other federal or state law, insofar
as such losses, claims, damages, liabilities or expenses (or actions or proceedings, whether commenced or threatened, in respect
thereof) arise out of or are based upon any untrue statement of any material fact contained in any registration statement prepared
and filed by the Company under which Registrable Securities were registered under the Securities Act, any preliminary prospectus,
final prospectus or summary prospectus contained therein, or any amendment or supplement thereto, or any omission to state therein
a material fact required to be stated or necessary to make the statements therein in light of the circumstances in which they
were made not misleading, or any violation or alleged violation of the Securities Act, the Exchange Act, any state securities
law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law in connection
with this Agreement; and the Company shall reimburse the Holder, and each such director, officer, partner, underwriter and controlling
person for any legal or any other expenses reasonably incurred by them in connection with investigating, defending or settling
any such loss, claim, damage, liability, action or proceeding; provided, that such indemnity agreement found in this Section
8(a) shall in no event exceed the net proceeds from the PPO, as applicable, received by the Company; and provided further,
that the Company shall not be liable in any such case (i) to the extent that any such loss, claim, damage, liability (or action
or proceeding in respect thereof) or expense arises out of or is based upon an untrue statement in or omission from such registration
statement, any such preliminary prospectus, final prospectus, summary prospectus, amendment or supplement in reliance upon and
in conformity with written information furnished to the Company by the Holder specifically for use in the preparation thereof
or (ii) if the person asserting any such loss, claim, damage, liability (or action or proceeding in respect thereof) who purchased
the Registrable Securities that are the subject thereof did not receive a copy of an amended preliminary prospectus or the final
prospectus (or the final prospectus as amended or supplemented) at or prior to the written confirmation of the sale of such Registrable
Securities to such person because of the failure of such Holder or underwriter to so provide such amended preliminary or final
prospectus and the untrue statement or omission of a material fact made in such preliminary prospectus was corrected in the amended
preliminary or final prospectus (or the final prospectus as amended or supplemented). Such indemnity shall remain in full force
and effect regardless of any investigation made by or on behalf of the Holders, or any such director, officer, partner, underwriter
or controlling person and shall survive the transfer of such shares by the Holder.

 

    	C-9

    	 

    

 

(b)         As
a condition to including Registrable Securities in any registration statement filed pursuant to this Agreement, each Holder agrees
to be bound by the terms of this Section 8 and to indemnify and hold harmless, to the fullest extent permitted by law, the Company,
its directors and officers, and each other person, if any, who controls the Company within the meaning of Section 15 of the Securities
Act, against any losses, claims, damages or liabilities, joint or several, to which the Company or any such director or officer
or controlling person may become subject under the Securities Act, the Exchange Act, or any other federal or state law, to the
extent arising out of or based solely upon: (x) such Holder’s failure to comply with the prospectus delivery requirements
of the Securities Act or (y) any untrue or alleged untrue statement of a material fact contained in any registration statement,
any prospectus, or any form of prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or arising
out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the
statements therein not misleading (i) to the extent, but only to the extent, that such untrue statement or omission is contained
in any information so furnished in writing by such Holder to the Company specifically for inclusion in the registration statement
or such prospectus or (ii) to the extent that (1) such untrue statements or omissions are based solely upon information regarding
such Holder furnished in writing to the Company by such Holder expressly for use therein, or to the extent that such information
relates to such Holder or such Holder’s proposed method of distribution of Registrable Securities and was reviewed and expressly
approved in writing by such Holder expressly for use in the Registration Statement, such prospectus or such form of prospectus
or in any amendment or supplement thereto or (2) in the case of an occurrence of an event of the type specified in Section 3(f)
hereof, the use by such Holder of an outdated or defective prospectus after the Company has notified such Holder in writing that
the prospectus is outdated or defective and prior to the receipt by such Holder of the advice contemplated in Section 3(f). In
no event shall the liability of any selling Holder hereunder be greater in amount than the dollar amount of the net proceeds received
by such Holder upon the sale of the Registrable Securities giving rise to such indemnification obligation.

 

(c)         Promptly
after receipt by an indemnified party of notice of the commencement of any action or proceeding involving a claim referred to
in this Section (including any governmental action), such indemnified party shall, if a claim in respect thereof is to be made
against an indemnifying party, give written notice to the indemnifying party of the commencement of such action; provided,
that the failure of any indemnified party to give notice as provided herein shall not relieve the indemnifying party of its obligations
under this Section, except to the extent that the indemnifying party is actually prejudiced by such failure to give notice. In
case any such action is brought against an indemnified party, unless in the reasonable judgment of counsel to such indemnified
party a conflict of interest between such indemnified and indemnifying parties may exist or the indemnified party may have defenses
not available to the indemnifying party in respect of such claim, the indemnifying party shall be entitled to participate in and
to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party and, after notice from the indemnifying
party to such indemnified party of its election so to assume the defense thereof, the indemnifying party shall not be liable to
such indemnified party for any legal or other expenses subsequently incurred by the latter in connection with the defense thereof,
unless in such indemnified party’s reasonable judgment a conflict of interest between such indemnified and indemnifying
parties arises in respect of such claim after the assumption of the defenses thereof or the indemnifying party fails to defend
such claim in a diligent manner, other than reasonable costs of investigation. Neither an indemnified nor an indemnifying party
shall be liable for any settlement of any action or proceeding effected without its consent. No indemnifying party shall, without
the consent of the indemnified party, consent to entry of any judgment or enter into any settlement, which does not include as
an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability
in respect of such claim or litigation. Notwithstanding anything to the contrary set forth herein, and without limiting any of
the rights set forth above, in any event any party shall have the right to retain, at its own expense, counsel with respect to
the defense of a claim.

 

    	C-10

    	 

    

 

(d)         If
an indemnifying party does or is not permitted to assume the defense of an action pursuant to Sections 9(c) or in the case of
the expense reimbursement obligation set forth in Sections 8(a) and (b), the indemnification required by Sections 8(a) and 8(b)
shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills
received or expenses, losses, damages, or liabilities are incurred.

 

(e)         If
the indemnification provided for in Section 8(a) or 8(b) is held by a court of competent jurisdiction to be unavailable to an
indemnified party with respect to any loss, liability, claim, damage or expense referred to herein, the indemnifying party, in
lieu of indemnifying such indemnified party hereunder, shall (i) contribute to the amount paid or payable by such indemnified
party as a result of such loss, liability, claim, damage or expense as is appropriate to reflect the proportionate relative fault
of the indemnifying party on the one hand and the indemnified party on the other (determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or omission relates to information supplied by the indemnifying
party or the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct
or prevent such untrue statement or omission), or (ii) if the allocation provided by clause (i) above is not permitted by applicable
law or provides a lesser sum to the indemnified party than the amount hereinafter calculated, not only the proportionate relative
fault of the indemnifying party and the indemnified party, but also the relative benefits received by the indemnifying party on
the one hand and the indemnified party on the other, as well as any other relevant equitable considerations. No indemnified party
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution
from any indemnifying party who was not guilty of such fraudulent misrepresentation.

 

(f)         Other
Indemnification. Indemnification similar to that specified in this Section (with appropriate modifications) shall be given
by the Company and each Holder of Registrable Securities with respect to any required registration or other qualification of securities
under any federal or state law or regulation or governmental authority other than the Securities Act.

 

9.            Rule
144. With a view to making available to the Holders the benefits of Rule 144 and any other rule or regulation of the Commission
that may at any time permit the Holders to sell the Registrable Securities to the public without registration, the Company agrees,
until the earlier of such time as the Investor Warrants are no longer outstanding or the Holders no longer own any Registrable
Securities: (i) to make and keep public information available as those terms are understood in Rule 144, (ii) to file with the
Commission in a timely manner all reports and other documents required to be filed by an issuer of securities registered under
the Securities Act or the Exchange Act pursuant to Rule 144, (iii) to furnish in writing upon such Holder’s request a written
statement by the Company that it has complied with the reporting requirements of Rule 144 and of the Securities Act and the Exchange
Act, and to furnish to such Holder a copy of the most recent annual or quarterly report of the Company, and such other reports
and documents so filed by the Company as may be reasonably requested in availing such Holder of any rule or regulation of the
Commission permitting the selling of any such Registrable Securities without registration and (iv) to undertake any additional
actions commercially reasonably necessary to maintain the availability of the use of Rule 144.

 

    	C-11

    	 

    

 

10.           Independent
Nature of Each Purchaser’s Obligations and Rights. The obligations of each Purchaser under this Agreement are several
and not joint with the obligations of any other Purchaser, and each Purchaser shall not be responsible in any way for the performance
of the obligations of any other Purchaser under this Agreement. Nothing contained herein and no action taken by any Purchaser
pursuant hereto, shall be deemed to constitute such Purchasers as a partnership, an association, a joint venture, or any other
kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such
obligations or the transactions contemplated by this Agreement. Each Purchaser shall be entitled to independently protect and
enforce its rights, including without limitation the rights arising out of this Agreement, and it shall not be necessary for any
other Purchaser to be joined as an additional party in any proceeding for such purpose.

 

		11.	Miscellaneous.

 

(a)         Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the United States of America and the
State of New York, both substantive and remedial, without regard to New York conflicts of law principles. Any judicial proceeding
brought against either of the parties to this Agreement or any dispute arising out of this Agreement or any matter related hereto
shall be brought in the courts of the State of New York, New York County, or in the United States District Court for the Southern
District of New York and, by its execution and delivery of this Agreement, each party to this Agreement accepts the jurisdiction
of such courts. The foregoing consent to jurisdiction shall not be deemed to confer rights on any person other than the parties
to this Agreement.

 

(b)         Remedies.
Subject to Section 2(b) of this Agreement, in the event of a breach by the Company or by a Holder of any of their respective obligations
under this Agreement, each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted
by law and under this Agreement, including recovery of damages, shall be entitled to specific performance of its rights under
this Agreement. Subject to Section 2(b) of this Agreement, the Company and each Holder agree that monetary damages would not provide
adequate compensation for any losses incurred by reason of a breach by it of any of the provisions of this Agreement and hereby
further agrees that, in the event of any action for specific performance in respect of such breach, it shall not assert or shall
waive the defense that a remedy at law would be adequate.

 

(c)         Successors
and Assigns. Except as otherwise provided herein, the provisions hereof shall inure to the benefit of, and be binding upon,
the successors, Permitted Assignees, executors and administrators of the parties hereto.

 

(d)         No
Inconsistent Agreements. The Company has not entered, as of the date hereof, and shall not enter, on or after the date of
this Agreement, into any agreement with respect to its securities that would have the effect of impairing the rights granted to
the Holders in this Agreement or otherwise conflicts with the provisions hereof.

 

(e)         Entire
Agreement. This Agreement constitutes the full and entire understanding and agreement between the parties with regard to the
subjects hereof.

 

(f)         Notices,
etc. All notices or other communications which are required or permitted under this Agreement shall be in writing and sufficient
if delivered by hand, by facsimile transmission, by registered or certified mail, postage pre-paid, by electronic mail, or by
courier or overnight carrier, to the persons at the addresses set forth below (or at such other address as may be provided hereunder),
and shall be deemed to have been delivered as of the date so delivered:

 

    	C-12

    	 

    

 

If
to the Company to:

 

Cell
Source, Ltd.

65
Yigal Alon Street, 23rd Floor

Tel
Aviv 67433, Israel

Attention:
Itamar Shimrat, Chief Executive Officer

Email:
ishimrat@cell-source.com

 

with
copy to:

 

Sichenzia
Ross Friedman Ference LLP

61
Broadway, 32nd Floor

New
York, NY 10006

Attention:
Gregory Sichenzia, Esq. Facsimile: (212) 930-9725

 

If
to the Purchasers:

 

To
each Purchaser at the address set forth on the signature page hereto

 

or
at such other address as any party shall have furnished to the other parties in writing.

 

(g)         Delays
or Omissions. No delay or omission to exercise any right, power or remedy accruing to any Holder, upon any breach or default
of the Company under this Agreement, shall impair any such right, power or remedy of such Holder nor shall it be construed to
be a waiver of any such breach or default, or an acquiescence therein, or of any similar breach or default thereunder occurring;
nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter
occurring. Any waiver, permit, consent or approval of any kind or character on the part of any Holder of any breach or default
under this Agreement, or any waiver on the part of any Holder of any provisions or conditions of this Agreement, must be in writing
and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement, or
by law or otherwise afforded to any holder, shall be cumulative and not alternative.

 

(h)         Counterparts.
This Agreement may be executed in any number of counterparts, each of which shall be enforceable against the parties actually
executing such counterparts, and all of which together shall constitute one instrument. In the event that any signature is delivered
by facsimile transmission, such signature shall create a valid and binding obligation of the party executing (or on whose behalf
such signature is executed) with the same force and effect as if such facsimile signature page were an original thereof.

 

(i)         Severability.
In the case any provision of this Agreement shall be invalid, illegal or unenforceable, the validity, legality and enforceability
of the remaining provisions shall not in any way be affected or impaired thereby.

 

    	C-13

    	 

    

 

(j)         Amendments.
The provisions of this Agreement may be amended at any time and from time to time, and particular provisions of this Agreement
may be waived, with and only with an agreement or consent in writing signed by the Company and the Majority Holders. The Purchasers
acknowledge that by the operation of this Section, the Majority Holders may have the right and power to diminish or eliminate
all rights of the Purchasers under this Agreement.

 

[SIGNATURE
PAGES FOLLOW]

 

    	C-14

    	 

    

 

This
Registration Rights Agreement is hereby executed as of the date first above written.

 

	 	COMPANY:
	 	 
	 	CELL SOURCE,  LTD.
	 	 
	 	By:	 
	 	Name:	Itamar Shimrat
	 	Title:	Chief Executive Officer

 

THE
PURCHASER’S SIGNATURE TO THE SUBSCRIPTION AGREEMENT DATED OF EVEN DATE HEREWITH SHALL CONSTITUTE THE PURCHASER’S SIGNATURE
TO THIS REGISTRATION RIGHTS AGREEMENT.

 

    	C-15

    	 

    

 

ATTACHMENT
A

CELL
SOURCE, LTD.

SELLING
STOCKHOLDERS’ QUESTIONNAIRE

 

The
following information is requested from you in connection with the preparation and filing by Cell Source, Ltd. (the “Company”)
of a Registration Statement on Form S-1 or other appropriate form (the “Registration Statement”) with the Securities
and Exchange Commission (the “SEC”) covering the sale of shares of the Company’s Ordinary Shares, including
shares of Ordinary Shares underlying Warrants (the “Registrable Securities”) by certain stockholders of the Company.

 

We
would appreciate your answering all of the questions included in this questionnaire, even though your answers may be in the negative,
so that the Company will have a record of your responses for use in connection with the preparation of the Registration Statement.
It is requested that you give careful attention to each question and that you complete this questionnaire personally.

 

In
order to assist you in completing this questionnaire, certain terms used herein are defined in the appendix which is attached
to this questionnaire. Each of such defined terms has been bolded and italicized for identification. The term “person,”
as used in this questionnaire, means any natural person, company, government or political subdivision, agency or instrumentality
of a government.

 

After
you have completed the following questionnaire, please send the completed questionnaire by facsimile, (212) 930-9725, e-mail,
dmanno@srff.com, or overnight courier as soon as possible to the attention of David Manno, Esq. at Sichenzia Ross Friedman Ference
LLP, 61 Broadway, 32nd Floor, New York, NY 10006.

 

*********************

 

General
Information

 

1.            Please
provide your full name and address or the full name and address of the entity on whose behalf you are completing this questionnaire.
The address may be a business, mailing or residence address.

 

	Name:	 
	 	 
	Address:	 

 

	2.	Name the Control Person of your organization:
    	 

 

		3.	(a) Are
                                         you a broker-dealer registered pursuant to Section 15 of the Exchange Act?

 

...
Yes.

...
No.

 

    	C-16

    	 

    

 

 

(b)
If your response to Item 3(a) above is no, are you an "affiliate" of a broker-dealer registered pursuant to Section
15 of the Exchange Act?

 

...
Yes.

...
No.

 

For
the purposes of this Item 3(b), an "affiliate" of a registered broker-dealer shall include any company that directly,
or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, such broker-dealer,
and does not include any individuals employed by such broker-dealer or its affiliates.

 

(c)
Full legal name of person through which you hold the Registrable Securities—(i.e. name of your broker, if applicable, through
which your Registered Securities are held):

 

	 	Name of broker:	 
	 	 	 
	 	Contact person:	 
	 	 	 
	 	Telephone No.:	 

 

Securities
 Holdings

 

Please
fill in all blanks in the following questions related to your beneficial ownership of the Company’s Ordinary
Shares. Generally, the term “beneficial ownership” refers to any direct or indirect interest in the
securities which entitles you to any of the rights or benefits of ownership, even though you may not be the holder of record of
the securities. For example, securities held in “street name” over which you exercise voting or investment power would
be considered beneficially owned by you. Other examples of indirect ownership include ownership by a partnership
in which you are a partner or by an estate or trust of which you or any member of your immediate family is a beneficiary.
Ownership of securities held in the names of your spouse, minor children or other relatives who live in the same household may
be attributed to you.

 

If
you have any reason to believe that any interest in securities of the Company which you may have, however remote, is a beneficial
interest, please describe such interest. For purposes of responding to this questionnaire, it is preferable to err on the side
of inclusion rather than exclusion. Where the SEC’s interpretation of beneficial ownership would require disclosure
of your interest or possible interest in certain securities of the Company, and you believe that you do not actually possess the
attributes of beneficial ownership, an appropriate response is to disclose the interest and at the same time disclaim
beneficial ownership of the securities.

 

    	C-17

    	 

    

 

Please
indicate the amount of Ordinary Shares of the Company or any of its subsidiaries which you beneficially owned as
of the date hereof.

 

For
each holding:

 

		•	State
                                         the nature of the holding (i.e., held in your own name, jointly, as a trustee
                                         or beneficiary of a trust, as a custodian, as an executor, in discretionary accounts,
                                         by your spouse or minor children, by a partnership of which you are a partner, etc.),
                                         and

 

		•	State
                                         whether you are the beneficial owner by reason of (i) sole voting power,
                                         (ii) shared voting power, (iii) sole investment power, (iv) shared investment power,
                                         (v) the right to acquire stock within 60 days of the end of the calendar year, and/or
                                         (vi) the right to acquire stock with the purpose of changing or influencing control.

 

		•	Indicate
                                         in the Remarks column whether you have sole or shared voting or investment power with
                                         respect to any such securities, and in what capacity (i.e., individual, general
                                         partner, trustee) you have such power or powers.

 

		•	If
                                         you wish to disclaim beneficial ownership of any shares listed, so indicate
                                         by writing the word “Disclaim” in the Remarks column below; you understand
                                         that such shares will be shown separately from your beneficial holdings and an appropriate
                                         disclaimer set forth.

 

		•	If
                                         any of the shares listed are subject to any claim, encumbrance, pledge or lien, so indicate
                                         in the Remarks column.

 

		1.	Your Interest
                                         in the Registrable Securities.

 

		(a)	State
                                         the number of such Registrable Securities beneficially owned by you.

 

	 	 

 

(b)         Other
than as set forth in your response to Item 1(a) above, do you beneficially own any other securities of the Company?

 

...
Yes.

 

...
No.

 

    	C-18

    	 

    

 

(c)           If
your answer to Item 1(b) above is yes, state the type, the aggregate amount and CUSIP No. (if applicable) of such other securities
of the Company beneficially owned by you:

 

	 	Type:	 
	 	 	 
	 	Aggregate amount:	 
	 	 	 
	 	CUSIP No.:	 

 

(d)           Did
you acquire the securities listed in Item 1(a) above in the ordinary course of business?

 

...
Yes.

 

...
No.

 

(e)           At
the time of your purchase of the securities listed in Item 1(a) above, did you have any agreements or understandings, directly
or indirectly, with any person to distribute the securities?

 

...
Yes.

 

...
No.

 

(f)           If
your response to Item 1(e) above is yes, please describe such agreements or understandings:

 

	 
	 
	 
	 
	 

 

		2.	Nature
                                         of Your Beneficial Ownership.

 

(a)         Does
someone other than yourself have Control over the securities listed in Item 1(a) above?

 

...
Yes.

 

...
No.

 

(b)         If
your response to Item 2(a) above is yes, name your controlling shareholder(s) or other person who has the ability to exercise
control over you (the "Controlling Entity"). If the Controlling Entity is not a natural person and is not a publicly
held entity, name each shareholder of such Controlling Entity. If any of these named shareholders are not natural persons or publicly
held entities, please provide the same information. This process should be repeated until you reach natural persons or a publicly
held entity.

 

    	C-19

    	 

    

 

		(A)(i)	Full
                                         legal name of Controlling Entity(ies) or natural person(s) with who have sole or shared
                                         voting or dispositive power over the Registrable Securities:

Business
address (including street address) (or residence if no business address), telephone number and facsimile number of such person(s):

	 	Address:	 
	 	 	 	 
	 	Telephone:	 
	 	 	 	 
	 	Fax:	 
	 	 	 	 
	 	Name of shareholder:;	 
	 	 	 
	 	 	 	 
	 	 	 
	 	 	 	 

 

		(B)(i)	Full
                                         legal name of Controlling Entity(ies):

	 	 	 
	 	 	 	 

 

Business
address (including street address) (or residence if no business address), telephone number and facsimile number of such person(s):

 

	 	Address:	 
	 	 	 	 
	 	Telephone:	 
	 	 	 	 
	 	Fax:	 
	 	 	 	 
	 	Name of shareholders:	 
	 	 	 	 

 

If
you need more space for this response, please attach additional sheets of paper. Please be sure to indicate your name and the
number of the item being responded to on each such additional sheet of paper, and to sign each such additional sheet of paper
before attaching it to this Questionnaire. Please note that you may be asked to answer additional questions depending on your
responses to the following questions.

 

    	C-20

    	 

    

 

		3.	5% Stockholders

 

To
the best of my knowledge, all persons (including myself and my associates and including corporations, partnerships,
trusts, associations and other such groups) who beneficially own more than 5% of any class of the Company’s
stock are described below:

 

	Name
    of
 Beneficial
 Owner	 	 	Class
    of Shares
 Beneficially
 Owned	 	 	Holder
    of Voting
 or Investment
 Power	 
	 		 	 	 		 	 	 		 
	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 

 

    	C-21

    	 

    

 

		4.	No Adverse
                                         Interest

 

All
interests I or my associates have or will have that are adverse to the Company interests in any pending or contemplated
legal proceeding or government investigation to which the Company is or will be a party (or to which its property may be subject)
are described below:

 

    	C-22

    	 

    

 

		5.	Voting
                                         Arrangement

 

All
voting trusts or similar agreements or arrangements of which I have knowledge under which more than 5% of the Company’s
outstanding Ordinary Shares, on an as converted basis, is held or to be held are described below:

 

	Names
    and Addresses of Voting Trustees	 	 	Voting
    Rights and Other Powers

    Under Trust, Agreement or Arrangement	 
	 		 	 	 		 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 

 

    	C-23

    	 

    

 

		6.	Change
                                         in Control

 

All
arrangements of which I have knowledge, including any pledge by any person of securities
of the Company, the operations of which may at a subsequent date result in a change in control
of the Company, are described below:

 

    	C-24

    	 

    

 

Transactions
with the Company

 

1.         Information
regarding all material interests of yours or your associates in any actual or proposed transaction during the last
three fiscal years to which the Company was or is to be a party and that are identified under “Securities Holdings”
above) is provided below. Further, no such transaction need be described if:

 

(a)        the
amount involved (including all periodic installments in the case of any lease or other agreement provided for periodic payments
or installments and including the value of all transactions In a series of similar transactions) does not exceed $60,000;

 

(b)        the
rates or charges involved in the transaction are fixed by law or governmental authority or determined by competitive bids;

 

(c)        the
services involved are as a bank depositary of funds, transfer agent, registrar, trustee under a trust indenture or other similar
service;

 

(d)        my
interest arises solely from my ownership of securities of the Company and I received no extra or special benefit not shared on
a pro rata basis by all other holders of securities in the same class;

 

(e)        my
interest in the corporation that is a party to the transaction is solely as a director; or

 

(f)         my
interest arose solely as an officer and/or director of the Company (e.g., my compensation arrangement with the Company).

 

Description:

 

    	C-25

    	 

    

 

AFFILIATION
WITH ACCOUNTANTS OR ATTORNEYS

 

Described
below is any interest, affiliation or connection you have with any law firm or accounting firm that has been retained by the Company
during the last three fiscal years or is proposed to be retained by the Company:

 

    	C-26

    	 

    

 

Contracts
with the Company

 

Described
below are all contracts with the Company or in which the Company has a beneficial interest, or to which the Company has succeeded
by assumption or assignment, to which you or any of your associates is a party, which are to be performed in whole
or in part at or after the date of the proposed filing of the Registration Statement, or which were made not more than two years
prior thereto:

 

    	C-27

    	 

    

 

FINRA-Related
 Questions

 

1.        Are
you (i) a “member” of the Financial Industries Regulatory Authority, Inc. (“FINRA”), (ii) an “affiliate”
of a member of the FINRA, (iii) a “person associated with a member” or “associated person of a member”
of the FINRA or (iv) associated with an “underwriter or related person” with respect to the proposed public offering
of the Company’s securities?

 

	 	Yes         	 	No        

 

For
the sole purpose of this Question: (i) the FINRA defines a “member” as being either any broker or dealer admitted
to membership in the FINRA or any officer or partner of such a member or the executive representative of such member or the substitute
for such representative; (ii) the term “affiliate” means a person that directly, or indirectly through one or more
intermediaries, controls, or is controlled by, or is in common control with the person specified. Persons who have acted or are
acting on behalf or for the benefit of a person include, but are not necessarily limited to, directors, officers, employees, agents,
consultants and sales representatives; (iii) the FINRA defines a “person associated with a member” or “associated
person of a member” as being every sole proprietor, partner, officer, director or branch manager of any member, or any natural
person occupying a similar status or performing similar functions, or any natural person engaged in the investment banking or
securities business who is directly or indirectly controlling or controlled by such member (for example, any employee), whether
or not any such person is registered or exempt from registration with the FINRA; and (iv) the term “underwriter or related
person” includes, with respect to a proposed offering, underwriters, underwriters’ counsel, financial consultants
and advisers, finders, members of the selling or distribution group, and any and all other persons associated with or related
to any such persons.

 

If
yes, kindly describe such relationship (whether direct or indirect) and please respond to

Questions
(2) and (3) below; if no, please proceed to Question (4).

 

2.        Please
set forth information as to all purchases and acquisitions (including contracts for purchase or acquisition) of securities of
the Company by you, regardless of the time acquired or the source from which derived:

 

	Seller or	 	Amount and	 	Price or Other	 	 
	Prospective
    Seller	 	Nature
    of Securities	 	Consideration	 	Date
		 		 		 	
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 

 

3.        In
connection with your direct or indirect affiliation or association with a “member” of the FINRA as set forth above
in Question (1), please furnish the identity of such FINRA member and any information, if known, as to whether such FINRA member
intends to participate in any capacity in this proposed initial public offering, including the details of such participation:

 

    	C-28

    	 

    

 

4.        Please
describe any underwriting compensation and arrangement or any dealings known to you between any “underwriter or related
person”, “member” of the FINRA, “affiliate” of a member of the FINRA, “person associated with
a member”, or “associated person of a member” of the FINRA on the one hand and the Company or controlling shareholder
thereof on the other hand, other than information relating to the proposed initial public offering of the Company:

 

5.        Please
set out below any information, if known, as to whether any “member” of the FINRA, any “underwriter or related
person”, “affiliate” or a member of the FINRA, “person associated with a member” or “associated
person of a member” of the FINRA may receive any portion of the net offering:

 

For
subscribers answering “Yes” to Item 1 above:

 

The
undersigned FINRA member form acknowledges receipt of the notice required by Article 3, Sections 28(a) and (b) of the Rules of
Fair Practice.

 

	 	 
	Name of FINRA Member Firm	 

 

	By:	 	 	Date:	 
	 	Authorized Officer	 	 

 

    	C-29

    	 

    

 

The
undersigned (including its donees or pledgees) intends to distribute the Registrable Securities listed above pursuant to the Registration
Statement only as follows (if at all): Such Registrable Securities may be sold from time to time directly by the undersigned or,
alternatively, through underwriters, broker-dealers or agents. If the Registrable Securities are sold through underwriters, broker-dealers
or agents, the Selling Holder will be responsible for underwriting discounts or commissions or agents' commissions. Such Registrable
Securities may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of sale, at varying
prices determined at the time of sale or at negotiated prices. Such sales may be effected in transactions (which may involve block
transactions) (i) on any national securities exchange or quotation service on which the Registrable Securities may be listed or
quoted at the time of sale, (ii) in the over-the-counter market, or (iii) in transactions otherwise than on such exchanges or
services or in the over-the-counter market.

 

I
understand that material misstatements or the omission of material facts in the Registration Statement may give rise to civil
and criminal liabilities to the Company, to each officer and director of the Company signing the Registration Statement and other
persons signing the Registration Statement. I will notify you and the Company of any misstatement of a material fact in the Registration
Statement or any amendment thereto, and of the omission of any material fact necessary to make the statements contained therein
not misleading, as soon as practicable after a copy of the Registration Statement or any such amendment has been provided to me.

 

I
confirm that the foregoing statements are correct, to the best of my knowledge and belief.

 

	Dated:	 	.	 
	 	 
	 	Very truly yours,
	 	 
	 	
	 	(Signature)
	 	 
	 	
	 	(Typed or Printed Name)

 

    	C-30

    	 

    

 

Definitions

 

The
term “arrangement” means any plan, contract, authorization or understanding whether or not set forth
in a formal document.

 

The
term “associate” as used throughout this questionnaire, means (a) any corporation or organization (other
than the Company) of which I am an officer, director or partner or of which I am, directly or indirectly, the beneficial owner
of 5% or more of any class of equity securities, (b) any trust or other estate in which I have a substantial beneficial interest
or as to which I serve as trustee or in a similar capacity, (c) my spouse, (d) any relative of my spouse or any relative of mine
who has the same home as me or who is a director or officer or key executive of the Company, (e) any partner, syndicate member
or person with whom I have agreed to act in concert with respect to the acquisition, holding, voting or disposition of shares
of the Company’s securities.

 

The
term “beneficially owned” when used in connection with the ownership of securities, means (a) any interest
in a security which entitles me to any of the rights or benefits of ownership even though I may not be the owner of record or
(b) securities owned by me directly or indirectly, including those held by me for my own benefit (regardless of how registered)
and securities held by others for my benefit (regardless of how registered), such as by custodians, brokers, nominees, pledgees,
etc., and including securities held by an estate or trust in which I have an interest as legatee or beneficiary, securities owned
by a partnership of which I am a partner, securities held by a personal holding company of which I am a stockholder, etc., and
securities held in the name of my spouse, minor children and any relative (sharing the same home). A “beneficial owner”
of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship
or otherwise has or shares:

 

(a)        voting
power which includes the power to vote, or to direct the voting of, such security;

and/or

 

(b)        investment
power which includes the power to dispose, or to direct the disposition, of such security.

 

The
term “control” means the possession, directly or indirectly, of the power to direct or cause the direction
of the management and policies of a person, whether through the ownership of voting securities, by contract or otherwise.

 

The
term “immediate family” means any relationship by blood, marriage or adoption, not more remote than
first cousin.

 

The
term “material,” when used in this questionnaire to qualify a requirement for the furnishing of information
as to any subject, limits the information required to those matters as to which an average prudent investor ought reasonably to
be informed before purchasing the Ordinary Shares of the Company.

 

    	C-31

    	 

    

 

EXHIBIT
D

 

CELL
SOURCE FINANCIAL STATEMENTS

 

    	 

    	 

    

 

 

[This
page intentionally left blank.]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]